{
  "runId": "agent-fs-2026-02-12T17-08-10-524Z",
  "generatedAt": "2026-02-12T17:23:15.828Z",
  "models": [
    "chatgpt-gpt-5.3-codex",
    "gpt-5.2",
    "kimi-k2.5",
    "glm-5",
    "gemini-2.5-pro",
    "gemini-flash-latest",
    "gemini-3-pro-preview",
    "gemini-3-flash-preview"
  ],
  "graderModel": "chatgpt-gpt-5.2",
  "reasoning": "medium",
  "tasks": [
    {
      "id": "tumor-vaccine-ici",
      "title": "mRNA tumor sensitization for checkpoint blockade",
      "sourceTitle": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
      "sourceUrl": "https://www.nature.com/articles/s41586-025-09006-8"
    },
    {
      "id": "gcse-chemistry-8-9",
      "title": "GCSE chemistry grade 8-9 multi-step quantitative solving",
      "sourceTitle": "GCSE Chemistry topic set (AQA specification-aligned, synthesized benchmark)",
      "sourceUrl": "https://www.aqa.org.uk/subjects/science/gcse/chemistry-8462/specification-at-a-glance"
    }
  ],
  "runs": 1,
  "projection": {
    "totalCases": 16,
    "estimatedAgentCostUsd": 0.1599,
    "estimatedGraderCostUsd": 0.224,
    "estimatedTotalCostUsd": 0.3839,
    "agentPromptTokens": 4200,
    "agentResponseTokens": 900,
    "graderPromptTokens": 5200,
    "graderResponseTokens": 350
  },
  "aggregate": {
    "cases": 16,
    "success": 9,
    "schemaPass": 10,
    "toolTracePass": 14,
    "graderPass": 9,
    "totalDurationMs": 3022585,
    "avgDurationMs": 188911.5625,
    "totalCostUsd": 1.42973145,
    "usage": {
      "promptTokens": 756249,
      "cachedTokens": 402729,
      "responseTokens": 58963,
      "thinkingTokens": 57710,
      "totalTokens": 872922
    }
  },
  "results": [
    {
      "model": "chatgpt-gpt-5.3-codex",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-tumor-vaccine-ici-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 65979,
      "agentCostUsd": 0.054303500000000005,
      "graderCostUsd": 0.013895000000000001,
      "totalCostUsd": 0.06819850000000001,
      "agentUsage": {
        "promptTokens": 16182,
        "cachedTokens": 4608,
        "responseTokens": 3415,
        "thinkingTokens": 511,
        "totalTokens": 20108
      },
      "graderUsage": {
        "promptTokens": 4052,
        "cachedTokens": 0,
        "responseTokens": 183,
        "thinkingTokens": 303,
        "totalTokens": 4538
      },
      "totalUsage": {
        "promptTokens": 20234,
        "cachedTokens": 4608,
        "responseTokens": 3598,
        "thinkingTokens": 814,
        "totalTokens": 24646
      },
      "modelVersions": [
        "chatgpt-gpt-5.3-codex"
      ],
      "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral mRNA vaccination can induce an interferon-rich tumor state that improves responsiveness to anti-PD-L1 immune checkpoint therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combination\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled repeat-experiment mouse cohort used to evaluate antitumor efficacy of intratumoral mRNA vaccine plus anti-PD-L1 treatment.\"\n    },\n    {\n      \"id\": \"mouse-matched-controls\",\n      \"label\": \"Mouse matched control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched controls including vaccine-only, ICI-only, and vehicle conditions used to benchmark combination effects in murine models.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Retrospective translational cohort of metastatic patients treated with ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of retrospective metastatic patients with prior SARS-CoV-2 mRNA vaccination before or around ICI treatment window.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Comparator subset of retrospective metastatic patients without prior SARS-CoV-2 mRNA vaccination in the analyzed cohort.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, complicating interpretation.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after vaccination.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated patients had better survival under ICI in retrospective comparison.\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed marked induction of type I interferon signaling after mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint-pathway expression increased, supporting combination with PD-L1 blockade.\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination treatment increased intratumoral cytotoxic T-cell infiltration.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome in tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Vaccination-associated tumor priming aligns with improved outcomes during checkpoint blockade, including better survival in the retrospective human cohort.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized, and tumor-type plus treatment-history heterogeneity limits causal interpretation.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling appears mechanistically necessary for the sensitization effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, so mechanistic dependence should be prospectively validated clinically.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The sensitization effect is conditional, because single-agent arms and non-mRNA particle controls did not replicate durable benefit.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        },\n        {\n          \"quote\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n          \"line_ref\": \"L37\"\n        },\n        {\n          \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        }\n      ],\n      \"caveat\": \"Some model systems showed stronger effects than others, indicating context dependence and limiting broad generalization across all tumor settings.\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may help checkpoint drugs work better, but proof in trials is still needed\",\n  \"plain_language_summary\": \"This study asked whether injecting an mRNA vaccine directly into tumors can make immune checkpoint therapy more effective. In mice, the vaccine increased inflammatory type I interferon signals, broadened the set of tumor peptides shown on MHC-I, raised PD-L1 expression, and increased CD8+ T-cell infiltration. These changes fit a biological model in which tumors become easier for immune cells to recognize, and therefore more responsive to anti-PD-L1 treatment. The paper also reported a retrospective analysis of 130 metastatic patients receiving checkpoint inhibitors, where previously vaccinated patients had better survival (p=0.01). However, that human comparison was not randomized and may be affected by confounding differences between groups. Overall, the findings are promising and mechanistically coherent, but they should be treated as hypothesis-supporting rather than definitive clinical proof until prospective randomized trials are completed.\",\n  \"what_is_new\": [\n    \"The study links intratumoral mRNA vaccination to broader tumor antigen presentation in immunopeptidomics readouts.\",\n    \"It proposes a stepwise mechanism from innate sensing to interferon signaling to improved checkpoint targetability.\",\n    \"It combines preclinical efficacy and mechanistic data with a human retrospective signal under ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human evidence comes from a retrospective, non-randomized cohort and is vulnerable to residual confounding.\",\n    \"Vaccination timing relative to ICI start varied across patients, which can bias outcome comparisons.\",\n    \"Tumor-type and prior-treatment heterogeneity make direct causal conclusions difficult.\",\n    \"Mouse model findings may not transfer uniformly to all human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer drug that releases inhibitory brakes on T cells, allowing stronger immune attack against tumor cells.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signaling molecules that can activate antiviral and antitumor programs, including antigen presentation pathways.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The set of peptide fragments displayed by MHC class I molecules on cells, which helps CD8+ T cells recognize targets.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study design that analyzes existing patient data after treatment, without random assignment to interventions.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized trials confirm that intratumoral mRNA vaccination improves ICI outcomes in patients?\",\n    \"Which tumor types and clinical contexts are most likely to benefit from this sensitization strategy?\",\n    \"What dosing, scheduling, and sequencing with checkpoint blockade maximize efficacy while maintaining safety?\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 24,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:12.086Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": ".",
            "timestamp": "2026-02-12T17:08:14.177Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:14.177Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:17.076Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:17.077Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:17.077Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:08:17.077Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:08:17.077Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:09:03.149Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:09:03.149Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:09:03.150Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:09:03.150Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 2,
            "coverage": 2,
            "usefulness": 2
          },
          "critical_issues": [],
          "summary": "The JSON outputs are faithful to the provided report: all quantitative values (mouse/human cohort sizes, immunopeptidome/MHC-I fractions, p-value, IFN score, PD-L1 and CD8 fold-changes) match the report (L19–L33) without inventing additional numbers. Core conditional/negative controls (single-agent limitations, empty lipid particle control, IFNAR1 blockade) are included and correctly attributed (L36–L39). The mechanistic narrative is consistent with the stated chain (L41–L46), and the human-evid"
        }
      }
    },
    {
      "model": "chatgpt-gpt-5.3-codex",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-gcse-chemistry-8-9-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 135211,
      "agentCostUsd": 0.08564975,
      "graderCostUsd": 0.01895075,
      "totalCostUsd": 0.1046005,
      "agentUsage": {
        "promptTokens": 27155,
        "cachedTokens": 14848,
        "responseTokens": 2875,
        "thinkingTokens": 3966,
        "totalTokens": 33996
      },
      "graderUsage": {
        "promptTokens": 3237,
        "cachedTokens": 0,
        "responseTokens": 180,
        "thinkingTokens": 769,
        "totalTokens": 4186
      },
      "totalUsage": {
        "promptTokens": 30392,
        "cachedTokens": 14848,
        "responseTokens": 3055,
        "thinkingTokens": 4735,
        "totalTokens": 38182
      },
      "modelVersions": [
        "chatgpt-gpt-5.3-codex"
      ],
      "agentFinalText": "Completed. Written output files:\n\n- [x] `output/problem_01.json`\n- [x] `output/problem_02.json`\n- [x] `output/problem_03.json`\n- [x] `output/problem_04.json`\n- [x] `output/problem_05.json`\n- [x] `output/problem_06.json`",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.02,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Using 3 significant figures from the given concentration and volumes gives 0.0200 mol dm-3 (reported as 0.02).\"\n  },\n  \"method\": \"Apply dilution directly with c1V1 = c2V2. Substitute c1 = 0.200 mol dm-3, V1 = 25.0 cm3, V2 = 250.0 cm3. So c2 = c1V1/V2 = 0.200 x 25.0 / 250.0 = 0.0200 mol dm-3. The tenfold increase in volume causes a tenfold decrease in concentration, matching the arithmetic result.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\",\n    \"c2 = c1V1 / V2\"\n  ],\n  \"line_refs\": [\"L16\", \"L29\"],\n  \"checks\": [\n    \"Final concentration is lower than initial because the solution was diluted.\",\n    \"Volume ratio 25.0 to 250.0 is 1:10, so concentration should be divided by 10.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"3 significant figures are appropriate from 5.00 g, 84.0%, and 44.0 Mr data, giving 1.85 g CO2.\"\n  },\n  \"method\": \"First find pure calcium carbonate mass: 5.00 g x 0.840 = 4.20 g CaCO3. From CaCO3 + 2HCl -> CaCl2 + CO2 + H2O, the mole ratio CaCO3:CO2 is 1:1, so mass scales by molar mass ratio. Therefore mass(CO2) = 4.20 x (44.0/100.1) = 1.846 g, which rounds to 1.85 g as the maximum CO2 mass.\",\n  \"key_equations\": [\n    \"mass(CO2) = mass(CaCO3 in sample) x Mr(CO2)/Mr(CaCO3)\",\n    \"mass(CaCO3 in sample) = total mass x purity fraction\"\n  ],\n  \"line_refs\": [\"L33\", \"L34\", \"L25\", \"L26\"],\n  \"checks\": [\n    \"CO2 mass must be less than the pure CaCO3 mass because only part of CaCO3 mass becomes CO2.\",\n    \"Acid is stated in excess, so CaCO3 amount limits the maximum product.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Given values are to 3-4 significant figures; 0.0702 mol dm-3 is reported to 3 significant figures.\"\n  },\n  \"method\": \"Use the neutralization stoichiometry H2SO4 + 2NaOH -> Na2SO4 + 2H2O. Moles NaOH used are 0.150 x 0.02340 = 0.00351 mol. Therefore moles H2SO4 = 0.00351/2 = 0.001755 mol. The acid volume is 25.00 cm3 = 0.02500 dm3, so concentration is c = n/V = 0.001755/0.02500 = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"n(H2SO4) = n(NaOH)/2\"\n  ],\n  \"line_refs\": [\"L15\", \"L39\", \"L40\"],\n  \"checks\": [\n    \"Because 2 mol NaOH react with 1 mol H2SO4, acid moles must be half the base moles.\",\n    \"Computed acid concentration is below base concentration, reasonable with similar titration volumes and 2:1 stoichiometry.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"Using the listed mean bond energies gives an estimated enthalpy change of -814 kJ mol-1.\"\n  },\n  \"method\": \"Use deltaH = sum(bonds broken) - sum(bonds formed). For CH4 + 2O2 -> CO2 + 2H2O, bonds broken are 4(C-H) + 2(O=O) = 4(413) + 2(498) = 2648 kJ mol-1. Bonds formed are 2(C=O in CO2) + 4(O-H) = 2(805) + 4(463) = 3462 kJ mol-1. Therefore deltaH = 2648 - 3462 = -814 kJ mol-1.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\"\n  ],\n  \"line_refs\": [\"L45\", \"L46\", \"L47\"],\n  \"checks\": [\n    \"Combustion is expected to be exothermic, so a negative deltaH is sensible.\",\n    \"More energy released in bond formation than absorbed in bond breaking gives a negative value.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"With 1.50 A and 30.0 min, the calculated deposited copper mass is 0.889 g (3 significant figures).\"\n  },\n  \"method\": \"Convert time: 30.0 min = 1800 s, so charge passed is 2700 C from 1.50 A over that interval. From Cu2+ + 2e- -> Cu, two moles of electrons deposit one mole of copper. Using F = 96500 C mol-1 gives n(Cu) = 2700/(2 x 96500) = 0.01399 mol. Multiply by Cu molar mass 63.55 to get m = 0.01399 x 63.55 = 0.889 g.\",\n  \"key_equations\": [\n    \"n(Cu) = Q/(2F)\",\n    \"m = n x Mr\"\n  ],\n  \"line_refs\": [\"L19\", \"L24\", \"L51\", \"L52\"],\n  \"checks\": [\n    \"Doubling either current or time would double deposited mass, matching electrolysis proportionality.\",\n    \"Result is less than 1 g for a moderate current over 30 minutes, which is physically plausible.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"unitless\",\n    \"precision_note\": \"Calculated from equilibrium concentrations and reported to 3 significant figures as 0.0736.\"\n  },\n  \"method\": \"Use Kc = [NO2]^2/[N2O4]. Convert given equilibrium moles to concentrations using the 2.00 dm3 vessel: [NO2] = 0.180/2.00 = 0.0900 mol dm-3 and [N2O4] = 0.220/2.00 = 0.110 mol dm-3. Then Kc = (0.0900^2)/0.110 = 0.00810/0.110 = 0.0736. As instructed, report Kc without units.\",\n  \"key_equations\": [\n    \"Kc = [NO2]^2 / [N2O4]\"\n  ],\n  \"line_refs\": [\"L20\", \"L56\", \"L57\", \"L58\"],\n  \"checks\": [\n    \"Kc is positive and dimensionless, consistent with the provided reporting instruction.\",\n    \"Since concentrations are below 0.2 mol dm-3, a Kc value below 1 is numerically reasonable here.\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 32,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:09:17.940Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:09:19.997Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:09:19.997Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:09:23.474Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:09:23.474Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:09:23.474Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:09:23.475Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:09:23.475Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:09:23.475Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:10:21.508Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:10:53.403Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "All six JSON outputs are consistent with the provided report data and equations, with no fabricated quantities. Calculations match the given constants/formulae (dilution, purity/stoichiometry, titration stoichiometry, bond-enthalpy estimate, Faraday’s law with Cu2+ + 2e- -> Cu, and Kc from equilibrium concentrations). Stated units and the instruction to report Kc as unitless are followed. Line references point to relevant numbered lines in the report (e.g., dilution L16/L29, purity and Mr data L"
        }
      }
    },
    {
      "model": "gpt-5.2",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/gpt-5-2-tumor-vaccine-ici-run-1",
      "success": false,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": false,
      "durationMs": 352691,
      "agentCostUsd": 0.1252818,
      "graderCostUsd": 0,
      "totalCostUsd": 0.1252818,
      "agentUsage": {
        "promptTokens": 40420,
        "cachedTokens": 19456,
        "responseTokens": 4007,
        "thinkingTokens": 2078,
        "totalTokens": 46505
      },
      "graderUsage": {
        "promptTokens": 0,
        "cachedTokens": 0,
        "responseTokens": 0,
        "thinkingTokens": 0,
        "totalTokens": 0
      },
      "totalUsage": {
        "promptTokens": 40420,
        "cachedTokens": 19456,
        "responseTokens": 4007,
        "thinkingTokens": 2078,
        "totalTokens": 46505
      },
      "modelVersions": [
        "gpt-5.2-2025-12-11"
      ],
      "agentFinalText": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine induce an interferon-rich inflammatory state that broadens antigen presentation and thereby sensitizes tumours to anti-PD-L1 immune checkpoint blockade, with supportive evidence in mice and a retrospective human cohort?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice pooled across repeat experiments\",\n      \"description\": \"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine in combination with anti-PD-L1, focused on tumour control and immune changes under combination treatment.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, and vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice pooled across matched controls\",\n      \"description\": \"Matched mouse controls spanning vaccine-only, ICI-only, and vehicle arms used to benchmark whether sensitization requires the combination and to assess null/conditional responses.\"\n    },\n    {\n      \"id\": \"human-metastatic-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients total\",\n      \"description\": \"Retrospective translational cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status for a survival comparison.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used as the exposed group in the survival comparison under ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for outcomes under ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis was retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumour-type mix and treatment-history heterogeneity limits causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumours.\",\n    \"Some mechanistic readouts were strongest in specific models rather than uniform across settings.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3% comparator\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6% comparator\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"Vaccinated subgroup vs unvaccinated subgroup in a retrospective metastatic ICI-treated cohort\",\n      \"interpretation\": \"In the retrospective cohort, prior SARS-CoV-2 mRNA vaccination status correlated with improved survival during ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0 baseline\",\n      \"interpretation\": \"mRNA vaccination in tumours produced a marked induction of a type I interferon response signature.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"After mRNA vaccination, PD-L1 pathway activity increased, potentially increasing targetability for anti-PD-L1 therapy.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"Combination therapy was associated with increased CD8+ T-cell infiltration into tumours.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination induces a type I interferon response in tumours.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"This report summarizes mechanistic induction primarily from tumour measurements and proposed chain; strength may vary by model system.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"These quantitative peptidome fractions are reported as preclinical readouts and may not directly translate to clinical tumour antigen presentation breadth.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The combined strategy (intratumoral mRNA vaccination plus anti-PD-L1) improves tumour control in mice and is consistent with improved outcomes in a retrospective human cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human evidence is explicitly retrospective and non-randomized, so the alignment with better outcomes cannot establish causality for vaccination improving ICI response.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Elimination of benefit with IFNAR1 blockade is a mechanistic control within the tested models; it does not prove the same dependency in all tumour types or in patients.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The retrospective human comparison is vulnerable to confounding and is not sufficient for direct causal interpretation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        },\n        {\n          \"quote\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n          \"line_ref\": \"L51\"\n        }\n      ],\n      \"caveat\": \"Despite these limitations, the analysis may still be hypothesis-generating for prospective trial design rather than definitive evidence of benefit.\"\n    }\n  ]\n}\n"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint blockade\",\n  \"plain_language_summary\": \"Many cancers do not respond well to immune checkpoint inhibitors (ICIs) because the tumour environment is not inflamed enough and tumour antigens are not presented strongly to the immune system. This study looked at whether delivering an mRNA vaccine directly into tumours can create a local interferon-driven immune activation that helps anti-PD-L1 therapy work better. In mouse tumour models, intratumoral mRNA vaccination was linked to stronger type I interferon signalling, broader antigen display (including a larger MHC-I peptidome), higher PD-L1 expression, and increased intratumoral CD8+ T-cell density. The paper also reports a retrospective analysis of 130 metastatic patients treated with ICIs, where outcomes differed by prior SARS-CoV-2 mRNA vaccination status (reported p=0.01). Because the human data are retrospective and non-randomized, the results should be treated as supportive but not proof that vaccination causes improved ICI benefit; prospective randomized studies are needed before changing clinical protocols.\",\n  \"what_is_new\": [\n    \"Links intratumoral mRNA vaccination to an interferon-rich tumour state that may enhance immune priming.\",\n    \"Reports broadened antigen presentation after mRNA vaccination, including expansion of the MHC-I peptidome.\",\n    \"Adds a retrospective patient cohort comparison suggesting better survival on ICI among previously vaccinated patients.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so confounding could explain the association.\",\n    \"Vaccination timing and patient/tumour heterogeneity limit direct causal interpretation.\",\n    \"Mouse model results may not translate one-to-one across all human tumours or treatment contexts.\",\n    \"Some mechanistic signals were strongest only in specific model systems rather than uniformly.\" \n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) to help T cells attack tumours, such as drugs targeting PD-1 or PD-L1.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; anti-PD-L1 drugs block this interaction to restore immune attack on tumours.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signalling molecules induced during innate sensing of nucleic acids, often triggering antiviral-like inflammation and antigen-presentation pathways.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cells that displays peptide fragments to CD8+ T cells; expanded MHC-I presentation can make tumours more visible to immune attack.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented on MHC molecules in a tissue; measuring it can indicate how many proteins are being shown to the immune system.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered directly into a tumour (rather than systemically), aiming to trigger local immune changes within the tumour microenvironment.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Do prospective randomized clinical trials confirm that mRNA vaccination strategies improve ICI response rates or survival?\",\n    \"Which tumour types and baseline immune states benefit most from interferon-driven priming and antigen-presentation expansion?\",\n    \"What is the optimal timing and dosing schedule of vaccination relative to starting checkpoint blockade?\",\n    \"Are there safety or tolerability constraints when driving strong interferon responses inside human tumours?\"\n  ]\n}\n"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 26,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "list_directory"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:12.294Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:15.431Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:17.743Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:17.743Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:08:17.743Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:08:17.743Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:19.473Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:08:48.812Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:09:46.367Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:09:46.367Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:09:46.367Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:09:46.367Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:10:01.504Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "error": "LLM JSON call failed after 2 attempt(s)"
      }
    },
    {
      "model": "gpt-5.2",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/gpt-5-2-gcse-chemistry-8-9-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 181595,
      "agentCostUsd": 0.18852819999999998,
      "graderCostUsd": 0.011067,
      "totalCostUsd": 0.19959519999999997,
      "agentUsage": {
        "promptTokens": 71428,
        "cachedTokens": 46464,
        "responseTokens": 3219,
        "thinkingTokens": 6546,
        "totalTokens": 81193
      },
      "graderUsage": {
        "promptTokens": 3636,
        "cachedTokens": 0,
        "responseTokens": 153,
        "thinkingTokens": 183,
        "totalTokens": 3972
      },
      "totalUsage": {
        "promptTokens": 75064,
        "cachedTokens": 46464,
        "responseTokens": 3372,
        "thinkingTokens": 6729,
        "totalTokens": 85165
      },
      "modelVersions": [
        "gpt-5.2-2025-12-11"
      ],
      "agentFinalText": "- [x] Wrote `output/problem_01.json`\n- [x] Wrote `output/problem_02.json`\n- [x] Wrote `output/problem_03.json`\n- [x] Wrote `output/problem_04.json`\n- [x] Wrote `output/problem_05.json`\n- [x] Wrote `output/problem_06.json`",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.02,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Quoted to 3 s.f. (0.0200 mol dm-3) based on given 0.200 mol dm-3 and 25.0 cm3.\"\n  },\n  \"method\": \"Use the dilution relationship c1V1 = c2V2. Here c1 = 0.200 mol dm-3 and V1 = 25.0 cm3, diluted to V2 = 250.0 cm3. Rearranging gives c2 = c1 × V1 / V2 = 0.200 × (25.0/250.0) = 0.200 × 0.100 = 0.0200 mol dm-3.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\",\n    \"c2 = c1V1/V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\",\n    \"L30\"\n  ],\n  \"checks\": [\n    \"Volume increases by a factor of 10, so concentration should drop by a factor of 10: 0.200 → 0.0200 mol dm-3.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"3 s.f., limited by 5.00 g sample mass and 84.0% purity (both 3 s.f.).\"\n  },\n  \"method\": \"First find the mass of pure CaCO3 in the limestone: 5.00 g × 0.840 = 4.20 g CaCO3. Calculate Mr values from the atomic data: Mr(CaCO3) = 40.1 + 12.0 + 3×16.0 = 100.1; Mr(CO2) = 12.0 + 2×16.0 = 44.0. Moles of CaCO3 = m/Mr = 4.20/100.1 = 0.04196 mol. From CaCO3 + 2HCl → CaCl2 + CO2 + H2O, the mole ratio CaCO3:CO2 is 1:1, so moles CO2 = 0.04196 mol. Mass of CO2 = n×Mr = 0.04196×44.0 = 1.846 g, which rounds to 1.85 g.\",\n  \"key_equations\": [\n    \"n = m/Mr\",\n    \"m = n×Mr\",\n    \"CaCO3 : CO2 = 1 : 1 (from the balanced equation)\"\n  ],\n  \"line_refs\": [\n    \"L14\",\n    \"L24\",\n    \"L33\",\n    \"L34\"\n  ],\n  \"checks\": [\n    \"If the sample were 100% CaCO3, CO2 mass would be 5.00×(44.0/100.1) ≈ 2.20 g; at 84.0% purity, expect ≈ 1.85 g, consistent.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"3 s.f., limited by NaOH concentration 0.150 mol dm-3 (3 s.f.).\"\n  },\n  \"method\": \"Convert the NaOH volume to dm3: 23.40 cm3 = 0.02340 dm3. Moles of NaOH = cV = 0.150 × 0.02340 = 0.00351 mol. From H2SO4 + 2NaOH → Na2SO4 + 2H2O, 2 mol NaOH react with 1 mol H2SO4, so moles H2SO4 = 0.00351/2 = 0.001755 mol. Convert the acid volume: 25.00 cm3 = 0.02500 dm3. Concentration of H2SO4 = n/V = 0.001755/0.02500 = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n/V\",\n    \"n = cV\",\n    \"H2SO4 : NaOH = 1 : 2 (from the balanced equation)\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\",\n    \"L41\"\n  ],\n  \"checks\": [\n    \"Moles NaOH is about 3.5×10^-3; halving gives ~1.75×10^-3 mol acid in 0.025 dm3, so c should be ~0.07 mol dm-3.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"Rounded to the nearest kJ mol-1; mean bond energies are given as whole-number estimates.\"\n  },\n  \"method\": \"Use ΔH = Σ(bonds broken) − Σ(bonds formed). For CH4 + 2O2 → CO2 + 2H2O: bonds broken are 4×(C–H) from CH4 and 2×(O=O) from 2O2. So Σbroken = 4×413 + 2×498 = 1652 + 996 = 2648 kJ mol-1. Bonds formed are 2×(C=O) in CO2 and 4×(O–H) in 2H2O (each H2O has 2 O–H bonds). So Σformed = 2×805 + 4×463 = 1610 + 1852 = 3462 kJ mol-1. Therefore ΔH = 2648 − 3462 = −814 kJ mol-1 (exothermic).\",\n  \"key_equations\": [\n    \"ΔH = Σ(bonds broken) − Σ(bonds formed)\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"Combustion reactions are expected to be exothermic, so a negative ΔH is sensible.\",\n    \"Magnitude is hundreds of kJ mol-1, consistent with typical combustion enthalpies estimated by bond energies.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"3 s.f., limited by 1.50 A, 30.0 min, and F = 96,500 C mol-1 (all 3 s.f.).\"\n  },\n  \"method\": \"Convert time to seconds: 30.0 min × 60 = 1800 s. Charge passed Q = I×t = 1.50×1800 = 2700 C. Faraday constant gives charge per mole of electrons, so moles of electrons n(e−) = Q/F = 2700/96500 = 0.02798 mol. From Cu2+ + 2e− → Cu, 2 mol e− deposit 1 mol Cu, so n(Cu) = 0.02798/2 = 0.01399 mol. Using the molar mass of copper from the atomic data (63.55 g mol−1), mass Cu = 0.01399×63.55 = 0.8886 g, which rounds to 0.889 g.\",\n  \"key_equations\": [\n    \"Q = It\",\n    \"n(e−) = Q/F\",\n    \"n(Cu) = n(e−)/2\",\n    \"m = n×Mr\"\n  ],\n  \"line_refs\": [\n    \"L19\",\n    \"L24\",\n    \"L51\",\n    \"L52\"\n  ],\n  \"checks\": [\n    \"2700 C corresponds to about 0.028 mol e−; half of that is ~0.014 mol Cu, giving ~0.014×64 ≈ 0.9 g, consistent.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"unitless\",\n    \"precision_note\": \"3 s.f., limited by equilibrium moles (0.180, 0.220) and volume 2.00 dm3 (all 3 s.f.).\"\n  },\n  \"method\": \"For N2O4(g) ⇌ 2NO2(g), Kc = [NO2]^2/[N2O4]. Convert moles to concentrations using the 2.00 dm3 vessel: [NO2] = 0.180/2.00 = 0.0900 mol dm−3 and [N2O4] = 0.220/2.00 = 0.110 mol dm−3. Substitute: Kc = (0.0900)^2/0.110 = 0.00810/0.110 = 0.073636…, so Kc = 0.0736 (dimensionless).\",\n  \"key_equations\": [\n    \"Kc = [NO2]^2/[N2O4]\",\n    \"[species] = n/V\"\n  ],\n  \"line_refs\": [\n    \"L20\",\n    \"L56\",\n    \"L57\",\n    \"L58\"\n  ],\n  \"checks\": [\n    \"Because NO2 is less concentrated than N2O4 here, Kc should be less than 1; 0.0736 matches that expectation.\",\n    \"Recomputing via moles: Kc = (nNO2^2)/(nN2O4×V) = (0.180^2)/(0.220×2.00) ≈ 0.0736, consistent.\"\n  ]\n}\n"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 48,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "read_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:14:05.019Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:14:08.658Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:14:11.531Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:14:11.531Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:14:11.531Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:14:11.531Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:14:11.531Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:14:11.532Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:14:13.993Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:16:04.297Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:16:08.346Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:16:08.346Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:16:08.346Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:16:08.346Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:16:08.347Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:16:08.347Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:16:45.167Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:16:52.982Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:16:52.982Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "All six JSON outputs are consistent with the provided report data and equations, with no fabricated inputs or unsupported quantitative claims. Calculations for dilution (P01), purity/stoichiometry (P02), titration stoichiometry (P03), bond-enthalpy estimate (P04), electrolysis via Faraday’s law (P05), and equilibrium constant Kc (P06) are numerically correct and appropriately rounded/qualified. Key caveats are respected where applicable (e.g., mean bond energies as estimates; Kc reported unitle​"
        }
      }
    },
    {
      "model": "kimi-k2.5",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/kimi-k2-5-tumor-vaccine-ici-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 45654,
      "agentCostUsd": 0.024471600000000003,
      "graderCostUsd": 0.0170485,
      "totalCostUsd": 0.041520100000000004,
      "agentUsage": {
        "promptTokens": 31061,
        "cachedTokens": 16896,
        "responseTokens": 4761,
        "thinkingTokens": 0,
        "totalTokens": 35822
      },
      "graderUsage": {
        "promptTokens": 4542,
        "cachedTokens": 0,
        "responseTokens": 187,
        "thinkingTokens": 463,
        "totalTokens": 5192
      },
      "totalUsage": {
        "promptTokens": 35603,
        "cachedTokens": 16896,
        "responseTokens": 4948,
        "thinkingTokens": 463,
        "totalTokens": 41014
      },
      "modelVersions": [
        "accounts/fireworks/models/kimi-k2p5"
      ],
      "agentFinalText": "All required output files have been written successfully. Here is the completion checklist:\n\n## Written Output Files Checklist\n\n| File | Status | Description |\n|------|--------|-------------|\n| ✅ `output/study_overview.json` | Written | Paper metadata, core research question, 5 cohorts with sample sizes, 5 major limitations |\n| ✅ `output/quantitative_findings.json` | Written | 6 quantitative findings (Q01-Q06) and 4 controls/null results with line references |\n| ✅ `output/claim_audit.json` | Written | 5 audited claims (C01-C05) with strength ratings, evidence quotes with line refs, and caveats |\n| ✅ `output/public_summary.json` | Written | Headline, plain-language summary, key innovations, caution notes, glossary (6 terms), and open questions |\n\n**All files:**\n- Use only relative paths as required\n- Contain valid JSON\n- Satisfy their respective schema constraints\n- Derive all content from `input/report.md`\n- Include proper line references (L19-L55) from the report\n- Use exact quotes where required by the schemas",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of mRNA vaccines create an interferon-rich inflammatory state that improves tumor sensitivity to anti-PD-L1 checkpoint blockade therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled across repeat experiments testing intratumoral mRNA vaccine combined with anti-PD-L1 checkpoint blockade.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Pooled across matched controls including vaccine only, ICI only, and vehicle treatment arms.\"\n    },\n    {\n      \"id\": \"human-retrospective-total\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective cohort with no prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling that primes tumors for improved response to immune checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination induces a broader peptide repertoire display on MHC-I, enhancing tumor visibility to T cells and increasing CD8+ T-cell infiltration.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination increases PD-L1 expression in tumor tissue, making the checkpoint axis more targetable and creating a biological rationale for combination with anti-PD-L1 therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation from the retrospective human data.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Patients with prior SARS-CoV-2 mRNA vaccination showed improved survival under ICI treatment compared to unvaccinated patients in retrospective analysis.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"The retrospective design means residual confounding is likely, vaccination timing relative to ICI initiation varied across patients, and tumor-type heterogeneity limits causal inference.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The combination of intratumoral mRNA vaccination with anti-PD-L1 checkpoint blockade improves tumor control in preclinical models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\n          \"line_ref\": \"L19\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and prospective randomized studies are required before clinical protocol changes are justified.\"\n    }\n  ]\n}\n"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"headline\": \"mRNA Vaccines Show Promise in Making Tumors More Responsive to Cancer Immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are powerful cancer drugs that help the immune system recognize and attack tumors, but they don't work well for many patients because some tumors are 'invisible' to immune cells. This study investigated whether mRNA vaccines, similar to those used for COVID-19, could be delivered directly into tumors to make them more sensitive to immunotherapy. In laboratory experiments with mice, injecting mRNA into tumors triggered an immune alarm system (called type I interferon response) that made cancer cells display more signals on their surface, helping immune cells find them. When combined with checkpoint inhibitor drugs, this approach improved tumor control. The researchers also analyzed medical records of cancer patients who had received COVID-19 mRNA vaccines before immunotherapy and found they had better survival outcomes than unvaccinated patients. However, this human data comes from a retrospective analysis, not a randomized trial, so it cannot prove cause-and-effect. The findings suggest a promising biological mechanism but require confirmation in prospective clinical trials before changing treatment protocols.\",\n  \"what_is_new\": [\n    \"mRNA vaccines can be delivered directly into tumors to create an inflammatory environment that primes the immune system for better response to checkpoint blockade drugs.\",\n    \"Prior SARS-CoV-2 mRNA vaccination in cancer patients was associated with improved survival during subsequent immunotherapy treatment.\",\n    \"The sensitization mechanism involves type I interferon signaling that expands the tumor antigen display on MHC-I molecules, making cancer cells more visible to CD8+ T cells while simultaneously increasing PD-L1 expression to create a targetable checkpoint axis.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival data comes from a retrospective analysis of patient records, not a randomized controlled trial, so hidden factors (confounding variables) may explain the observed association.\",\n    \"Timing of vaccination relative to cancer treatment varied among patients, making it difficult to determine the optimal schedule for any potential benefit.\",\n    \"The patient group included mixed cancer types and treatment histories, so results may not apply equally to all cancers.\",\n    \"Mouse tumor models do not perfectly replicate human cancers, so laboratory findings may not translate directly to human patients.\",\n    \"Some of the biological mechanism data was strongest only in specific experimental models rather than consistently across all tested systems.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors (ICIs)\",\n      \"definition\": \"Drugs that block proteins like PD-L1 that tumors use to put brakes on immune cell attacks, allowing T cells to kill cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine using messenger RNA molecules that instruct cells to make specific proteins, triggering an immune response against those proteins.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The collection of protein fragments (peptides) displayed on the surface of cells by MHC class I molecules, which allows immune cells to survey what is inside the cell.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of signaling proteins produced by cells in response to viral infections or other threats that activate immune defenses and inflammation.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"A type of immune cell (cytotoxic T lymphocyte) that recognizes and kills cancer cells or infected cells displaying specific antigens on their surface.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that some cancer cells display to interact with PD-1 on T cells and suppress immune attack; blocking this interaction is the target of checkpoint inhibitor therapy.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized clinical trials confirm that mRNA vaccination improves immunotherapy outcomes, and what is the optimal timing and dosing schedule?\",\n    \"Which specific cancer types are most likely to benefit from mRNA vaccination as a sensitization strategy?\",\n    \"Can intratumoral mRNA delivery be practically implemented in human patients across different tumor locations and stages?\",\n    \"What are the long-term safety implications of combining mRNA vaccines with checkpoint blockade therapy?\"\n  ]\n}\n"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 30,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:11.537Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:12.322Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:12.323Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:13.377Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:13.378Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:08:13.378Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:08:13.378Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:08:30.685Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:08:30.685Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:08:30.685Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:08:30.685Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:08:31.767Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:08:31.768Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:08:31.768Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:08:31.768Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 4,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "Across the four JSON files, the outputs adhere closely to the provided report without introducing unsupported quantitative values or contradicting the stated design. The key study components are accurately represented: (1) mixed design (murine preclinical + retrospective human cohort) (L14–L16), (2) correct cohort sizes (mice 78/84; humans 130 with 43 vaccinated/87 unvaccinated) (L19–L23), (3) the main quantitative results (immunopeptidome and MHC-I coverage, p=0.01 survival association, IFN-I, "
        }
      }
    },
    {
      "model": "kimi-k2.5",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/kimi-k2-5-gcse-chemistry-8-9-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": true,
      "graderPass": false,
      "durationMs": 54723,
      "agentCostUsd": 0.0233105,
      "graderCostUsd": 0.0147035,
      "totalCostUsd": 0.038014,
      "agentUsage": {
        "promptTokens": 29280,
        "cachedTokens": 17423,
        "responseTokens": 4818,
        "thinkingTokens": 0,
        "totalTokens": 34098
      },
      "graderUsage": {
        "promptTokens": 3706,
        "cachedTokens": 0,
        "responseTokens": 355,
        "thinkingTokens": 232,
        "totalTokens": 4293
      },
      "totalUsage": {
        "promptTokens": 32986,
        "cachedTokens": 17423,
        "responseTokens": 5173,
        "thinkingTokens": 232,
        "totalTokens": 38391
      },
      "modelVersions": [
        "accounts/fireworks/models/kimi-k2p5"
      ],
      "agentFinalText": "## Completion Checklist\n\nAll required output files have been successfully written:\n\n- [x] `output/problem_01.json` - Dilution problem (HCl concentration calculation using c₁V₁=c₂V₂)\n- [x] `output/problem_02.json` - Stoichiometry + Purity problem (CO₂ mass from limestone)\n- [x] `output/problem_03.json` - Titration problem (H₂SO₄ concentration calculation)\n- [x] `output/problem_04.json` - Bond Energy Estimate problem (methane combustion enthalpy)\n- [x] `output/problem_05.json` - Electrolysis problem (copper mass deposited)\n- [x] `output/problem_06.json` - Equilibrium Constant problem (Kc for N₂O₄/NO₂ system)",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.02,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Calculated as 0.0200 mol dm-3 using dilution equation c1V1=c2V2 with 3 significant figures matching input data.\"\n  },\n  \"method\": \"Using the dilution equation c1V1 = c2V2, where c1 is the initial concentration (0.200 mol dm-3), V1 is the initial volume (25.0 cm3), and V2 is the final volume (250.0 cm3). The final concentration c2 is calculated as (0.200 × 25.0) / 250.0 = 0.0200 mol dm-3. Since all input values have 3 significant figures, the answer is reported to 3 significant figures.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\",\n    \"L30\"\n  ],\n  \"checks\": [\n    \"Dilution factor is 10x (250/25), so concentration should be 1/10 of original\",\n    \"0.200/10 = 0.0200 confirms the calculation\",\n    \"Final answer has correct units mol dm-3\",\n    \"Significant figures (3 sf) match the least precise input data\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "line_refs: Too big: expected array to have <=4 items"
          ],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"Calculated mass is 1.846 g, rounded to 1.85 g to maintain 3 significant figures consistent with input data.\"\n  },\n  \"method\": \"First calculate the mass of pure CaCO3 in the sample: 5.00 g × 0.840 = 4.20 g. Then calculate moles of CaCO3 using n = m/Mr: 4.20 g / 100.1 g/mol = 0.04196 mol. From the balanced equation CaCO3 + 2HCl -> CaCl2 + CO2 + H2O, the mole ratio of CaCO3 to CO2 is 1:1. Therefore moles of CO2 produced = 0.04196 mol. Finally, calculate mass of CO2: 0.04196 mol × 44.0 g/mol = 1.846 g, rounded to 1.85 g to 3 significant figures.\",\n  \"key_equations\": [\n    \"n = m / Mr\",\n    \"m(CO2) = n(CaCO3) × Mr(CO2)\"\n  ],\n  \"line_refs\": [\n    \"L25\",\n    \"L26\",\n    \"L33\",\n    \"L34\",\n    \"L36\"\n  ],\n  \"checks\": [\n    \"Mass of pure CaCO3 is 4.20 g (84% of 5.00 g)\",\n    \"Mole ratio CaCO3:CO2 is 1:1 from balanced equation\",\n    \"Molar mass of CO2 is 44.0 g/mol as stated in report\",\n    \"Final answer rounded to 3 significant figures\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Calculated concentration is 0.0702 mol dm-3 with 3 significant figures, consistent with the precision of the titration data provided.\"\n  },\n  \"method\": \"First convert the volume of NaOH to dm3: 23.40 cm3 = 0.02340 dm3. Calculate moles of NaOH using n = c × V: 0.150 mol dm-3 × 0.02340 dm3 = 0.00351 mol. From the balanced equation H2SO4 + 2NaOH -> Na2SO4 + 2H2O, the mole ratio of H2SO4 to NaOH is 1:2. Therefore moles of H2SO4 = 0.00351 / 2 = 0.001755 mol. Convert acid volume to dm3: 25.00 cm3 = 0.02500 dm3. Calculate concentration of H2SO4: c = n/V = 0.001755 mol / 0.02500 dm3 = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"n = c × V\",\n    \"c = n / V\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\",\n    \"L41\"\n  ],\n  \"checks\": [\n    \"Moles of NaOH calculated correctly as 0.00351 mol\",\n    \"Stoichiometric ratio H2SO4:NaOH = 1:2 applied correctly\",\n    \"Volume conversions from cm3 to dm3 are correct\",\n    \"Final concentration has appropriate significant figures (3 sf)\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -820,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"Calculated enthalpy change is -820 kJ mol-1 using mean bond energies, reported as integer consistent with bond energy data precision.\"\n  },\n  \"method\": \"Using the formula deltaH = sum(bonds broken) - sum(bonds formed). For the reaction CH4 + 2O2 -> CO2 + 2H2O: Bonds broken are 4 C-H bonds and 2 O=O bonds. Sum of bonds broken = 4(413) + 2(498) = 1652 + 996 = 2648 kJ mol-1. Bonds formed are 2 C=O bonds (in CO2) and 4 O-H bonds. Sum of bonds formed = 2(805) + 4(463) = 1610 + 1852 = 3462 kJ mol-1. Therefore deltaH = 2648 - 3462 = -814 kJ mol-1, which rounds to -820 kJ mol-1 when using the bond energy precision provided.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"4 C-H bonds and 2 O=O bonds broken in reactants\",\n    \"2 C=O bonds and 4 O-H bonds formed in products\",\n    \"Negative value indicates exothermic combustion reaction\",\n    \"Magnitude is reasonable for hydrocarbon combustion\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "line_refs: Too big: expected array to have <=4 items"
          ],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"Calculated mass of copper is 0.889 g, reported to 3 significant figures matching the precision of the current and time measurements.\"\n  },\n  \"method\": \"First convert time to seconds: 30.0 min × 60 s/min = 1800 s. Calculate charge Q using Q = I × t: Q = 1.50 A × 1800 s = 2700 C. Calculate moles of electrons using n(e-) = Q / F: n(e-) = 2700 C / 96500 C mol-1 = 0.02798 mol. From the half-equation Cu2+ + 2e- -> Cu, 2 moles of electrons produce 1 mole of copper. Therefore n(Cu) = 0.02798 / 2 = 0.01399 mol. Calculate mass of copper using m = n × Ar: m(Cu) = 0.01399 mol × 63.55 g/mol = 0.889 g.\",\n  \"key_equations\": [\n    \"Q = I × t\",\n    \"n(e-) = Q / F\",\n    \"m = n × Ar\"\n  ],\n  \"line_refs\": [\n    \"L17\",\n    \"L18\",\n    \"L19\",\n    \"L24\",\n    \"L51\",\n    \"L52\",\n    \"L53\"\n  ],\n  \"checks\": [\n    \"Time correctly converted to 1800 seconds\",\n    \"Charge calculated as 2700 Coulombs\",\n    \"Moles of electrons divided by 2 for copper deposition\",\n    \"Final mass reported to 3 significant figures\"\n  ]\n}\n"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "line_refs: Too big: expected array to have <=4 items"
          ],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"dimensionless\",\n    \"precision_note\": \"Calculated Kc is 0.0736, reported as dimensionless to 3 significant figures consistent with the equilibrium composition data provided.\"\n  },\n  \"method\": \"Calculate equilibrium concentrations by dividing moles by volume: [NO2] = 0.180 mol / 2.00 dm3 = 0.0900 mol dm-3, and [N2O4] = 0.220 mol / 2.00 dm3 = 0.110 mol dm-3. Apply the equilibrium constant expression Kc = [NO2]^2 / [N2O4]. Substitute the values: Kc = (0.0900)^2 / 0.110 = 0.00810 / 0.110 = 0.0736. The result is reported as dimensionless (unitless) as specified in the problem.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"Kc = [NO2]^2 / [N2O4]\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L20\",\n    \"L21\",\n    \"L56\",\n    \"L57\",\n    \"L58\"\n  ],\n  \"checks\": [\n    \"Concentration of NO2 is 0.0900 mol dm-3\",\n    \"Concentration of N2O4 is 0.110 mol dm-3\",\n    \"Kc expression correctly applied with squared NO2 term\",\n    \"Result is dimensionless as required\"\n  ]\n}\n"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 32,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "list_directory"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:09:03.727Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:09:04.361Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:09:04.361Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:09:05.402Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:09:28.011Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:09:28.012Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:09:28.012Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:09:28.012Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:09:28.012Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:09:28.012Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:09:31.372Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 5,
            "coverage": 4,
            "usefulness": 4
          },
          "critical_issues": [
            "Three outputs (P02, P05, P06) have invalid line reference arrays: the report validator flags `line_refs` as too long (>4 items). This violates the requirement that line references be valid/mappable and makes the JSON less reliable for downstream review.",
            "Because P02, P05, and P06 are flagged `groundingValid: false`, the outputs do not meet the stated pass criterion that line references must be valid and map to the numbered report lines.",
            "P04’s numerical result is computed as -814 kJ mol-1 from the provided bond energies, but the final answer is rounded to -820 kJ mol-1 without a clearly justified rounding rule tied to the report’s stated significant-figure expectations (the report does not specify rounding for bond-energy estimates). This is a smaller issue than the grounding failures but still a calibration/usefulness concern."
          ],
          "summary": "Most of the underlying chemistry calculations appear consistent with the data in the report (P01, P03, and the intermediate steps in P02/P05/P06 align with the given equations/constants and values on the cited lines). However, the submission fails overall because multiple JSON files have invalid/overlong `line_refs` arrays (explicit schema/grounding failures), which breaks the requirement that references be valid and usable for audit. Additionally, P04’s rounding from -814 to -820 kJ mol-1 is a弱"
        }
      }
    },
    {
      "model": "glm-5",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/glm-5-tumor-vaccine-ici-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 71663,
      "agentCostUsd": 0.049842199999999996,
      "graderCostUsd": 0.01835575,
      "totalCostUsd": 0.06819795,
      "agentUsage": {
        "promptTokens": 47071,
        "cachedTokens": 15312,
        "responseTokens": 4694,
        "thinkingTokens": 0,
        "totalTokens": 51765
      },
      "graderUsage": {
        "promptTokens": 4409,
        "cachedTokens": 0,
        "responseTokens": 345,
        "thinkingTokens": 415,
        "totalTokens": 5169
      },
      "totalUsage": {
        "promptTokens": 51480,
        "cachedTokens": 15312,
        "responseTokens": 5039,
        "thinkingTokens": 415,
        "totalTokens": 56934
      },
      "modelVersions": [
        "accounts/fireworks/models/glm-5"
      ],
      "agentFinalText": "## Completion Checklist\n\nAll required output files have been written successfully:\n\n| Output File | Schema | Status |\n|-------------|--------|--------|\n| `output/study_overview.json` | `schemas/study_overview.schema.json` | ✅ Written |\n| `output/quantitative_findings.json` | `schemas/quantitative_findings.schema.json` | ✅ Written |\n| `output/claim_audit.json` | `schemas/claim_audit.schema.json` | ✅ Written |\n| `output/public_summary.json` | `schemas/public_summary.schema.json` | ✅ Written |\n\nAll outputs:\n- Derive content from the report without invention\n- Use `L<number>` line refs from the report\n- Include exact quotes where required\n- Follow relative path conventions\n- Are valid JSON conforming to their respective schemas",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, and vehicle controls pooled across matched controls.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"A retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Patients within the retrospective cohort who had prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Patients within the retrospective cohort who did not have prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Interferon-associated antigen processing and presentation pathways increase after mRNA vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"A broader peptide repertoire appears on MHC-I after mRNA vaccination, improving tumor visibility to T cells.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Combined mRNA vaccination and checkpoint blockade intervention improves tumor control in mice.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C06\",\n      \"claim\": \"Vaccinated patients show improved survival outcomes under ICI treatment compared to unvaccinated patients.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely. Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"headline\": \"mRNA vaccines may help immune therapies fight cancer better, early research suggests.\",\n  \"plain_language_summary\": \"Scientists studied whether injecting mRNA vaccines directly into tumors could make cancer treatments called immune checkpoint inhibitors work better. These checkpoint inhibitor drugs help the immune system recognize and attack cancer, but they do not work for everyone. The researchers found that mRNA vaccination inside tumors triggered a strong immune response, making cancer cells more visible to the immune system. In mouse experiments, the combination treatment led to better tumor control. They also looked at human patients who had received COVID-19 mRNA vaccines before getting checkpoint inhibitor treatment for metastatic cancer. Those who had been vaccinated showed somewhat better survival outcomes. However, this was a backward-looking study, not a controlled trial, so we cannot be certain the vaccine caused the improvement. More research is needed before doctors should change how they treat cancer patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination was shown to expand the range of tumor proteins displayed to the immune system, from 37% to over 62%.\",\n    \"Type I interferon responses increased 3-fold after mRNA vaccination, revealing how the vaccine activates innate immunity in tumors.\",\n    \"PD-L1 levels in tumors rose 2.4-fold after vaccination, explaining why checkpoint inhibitors might work better in combination.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study looked back at existing medical records rather than conducting a new controlled trial, so unknown factors could explain the survival difference.\",\n    \"Patients received their vaccines at different times before starting cancer treatment, making it hard to know the best timing.\",\n    \"The study included different types of cancer and patients with various treatment histories, which complicates direct comparisons.\",\n    \"Results from mouse studies do not always translate directly to human patients, as biology can differ between species.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A type of vaccine that delivers genetic instructions (messenger RNA) to cells, teaching them to make a protein that triggers an immune response.\"\n    },\n    {\n      \"term\": \"Checkpoint inhibitor\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that normally suppress immune responses.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein found on some cells that binds to immune cells and tells them to slow down or stop; cancer cells sometimes use it to avoid immune attack.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Signaling proteins produced by cells in response to viruses and other threats; they help activate immune cells and boost the body's defenses.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"Molecules on the surface of cells that display protein fragments to immune cells, allowing the immune system to inspect cells for signs of infection or cancer.\"\n    },\n    {\n      \"term\": \"CD8+ T-cell\",\n      \"definition\": \"A type of white blood cell that can directly kill infected or cancerous cells; often called 'killer T cells' for their ability to destroy harmful cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would injecting mRNA vaccines into human tumors produce the same immune changes seen in mice?\",\n    \"What is the optimal timing between mRNA vaccination and starting checkpoint inhibitor treatment?\",\n    \"Does the type or location of cancer affect how well this combination therapy works?\",\n    \"Are the benefits seen in retrospective studies confirmed by prospective randomized clinical trials?\",\n    \"Could repeated mRNA vaccinations provide sustained sensitization or would side effects limit this approach?\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 24,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:11.689Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:13.079Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:13.079Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:14.740Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:14.740Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:08:14.740Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:08:14.740Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:08:23.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:08:30.960Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:08:37.220Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:08:48.701Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:08:59.652Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 4,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [
            "Evidence support for the specific claim of improved mouse tumor control is thinly grounded in the JSON: claim_audit C05 cites CD8+ T-cell density (L33) as supporting evidence, which is an immune-correlate and not itself a direct tumor-control endpoint. The report does assert improved tumor control (L46), but that line is part of the proposed mechanistic chain rather than a dedicated efficacy metric in the Quantitative Findings table (L25–L34). This is acceptable but should ideally be supported by explicit tumor-growth/response numbers if available.",
            "The public_summary phrase \"Type I interferon responses increased 3-fold\" is a rounded restatement of 3.1 vs 1.0 (L31). It is directionally correct and not misleading, but it is slightly less precise than the report’s stated normalized units."
          ],
          "summary": "Overall the outputs are faithful to the provided report: cohort sizes and design match (L13–L23), quantitative values are correctly reproduced with valid line references (L28–L33), key controls/null results are included (L36–L39), and major caveats about retrospective non-randomized human evidence and heterogeneity are covered (L48–L53). Claims are generally calibrated, especially for the human survival association (moderate strength with confounding caveat). The main minor weakness is that the\n"
        }
      }
    },
    {
      "model": "glm-5",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/glm-5-gcse-chemistry-8-9-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 94656,
      "agentCostUsd": 0.057549600000000006,
      "graderCostUsd": 0.01318975,
      "totalCostUsd": 0.07073935,
      "agentUsage": {
        "promptTokens": 47812,
        "cachedTokens": 22336,
        "responseTokens": 8627,
        "thinkingTokens": 0,
        "totalTokens": 56439
      },
      "graderUsage": {
        "promptTokens": 3737,
        "cachedTokens": 0,
        "responseTokens": 169,
        "thinkingTokens": 306,
        "totalTokens": 4212
      },
      "totalUsage": {
        "promptTokens": 51549,
        "cachedTokens": 22336,
        "responseTokens": 8796,
        "thinkingTokens": 306,
        "totalTokens": 60651
      },
      "modelVersions": [
        "accounts/fireworks/models/glm-5"
      ],
      "agentFinalText": "## Completion Checklist\n\nAll required output files have been written successfully:\n\n| Output File | Status | Problem Description |\n|------------|--------|---------------------|\n| `output/problem_01.json` | ✅ Written | Dilution calculation: c₂ = 0.0200 mol dm⁻³ |\n| `output/problem_02.json` | ✅ Written | Stoichiometry + Purity: m(CO₂) = 1.85 g |\n| `output/problem_03.json` | ✅ Written | Titration: c(H₂SO₄) = 0.0702 mol dm⁻³ |\n| `output/problem_04.json` | ✅ Written | Bond Energy: ΔH = -814 kJ mol⁻¹ |\n| `output/problem_05.json` | ✅ Written | Electrolysis: m(Cu) = 0.889 g |\n| `output/problem_06.json` | ✅ Written | Equilibrium: Kc = 0.0736 (dimensionless) |\n\nAll JSON outputs:\n- Conform to their respective schemas\n- Derive calculations from values in the report only\n- Include proper line references (L# format)\n- Use appropriate significant figures\n- Include method explanations and validation checks",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.0200,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Answer given to 3 significant figures, consistent with the precision of the initial concentration (0.200 mol dm-3) and volumes (25.0 cm3, 250.0 cm3).\"\n  },\n  \"method\": \"Using the dilution equation c1V1 = c2V2, where c1 = 0.200 mol dm-3 is the initial concentration, V1 = 25.0 cm3 is the initial volume, and V2 = 250.0 cm3 is the final volume. Rearranging gives c2 = c1V1/V2. Substituting values: c2 = (0.200 × 25.0) / 250.0 = 5.00 / 250.0 = 0.0200 mol dm-3. The concentration decreases by a factor of 10, consistent with a tenfold volume increase.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\"\n  ],\n  \"checks\": [\n    \"Dilution factor is 250.0/25.0 = 10, so concentration should decrease tenfold from 0.200 to 0.0200 mol dm-3.\",\n    \"Units consistent: mol dm-3 throughout the calculation.\",\n    \"Three significant figures maintained throughout as per GCSE conventions.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"Answer given to 3 significant figures, limited by the least precise input values: 5.00 g, 84.0%, and Mr(CO2) = 44.0 g mol-1.\"\n  },\n  \"method\": \"First, calculate the mass of pure CaCO3 in the limestone sample: mass(CaCO3) = 5.00 g × 0.840 = 4.20 g. Next, calculate moles of CaCO3 using n = m/Mr: n(CaCO3) = 4.20 g / 100.1 g mol-1 = 0.0420 mol. From the balanced equation (L34), the mole ratio CaCO3:CO2 is 1:1, so n(CO2) = 0.0420 mol. Finally, calculate mass of CO2: m(CO2) = n × Mr = 0.0420 mol × 44.0 g mol-1 = 1.85 g.\",\n  \"key_equations\": [\n    \"n = m / Mr\",\n    \"m = n × Mr\"\n  ],\n  \"line_refs\": [\n    \"L25\",\n    \"L26\",\n    \"L33\",\n    \"L34\"\n  ],\n  \"checks\": [\n    \"Purity calculation: 5.00 g × 0.840 = 4.20 g CaCO3 matches intermediate step.\",\n    \"Stoichiometry verified: 1 mol CaCO3 produces 1 mol CO2 from the balanced equation.\",\n    \"Final mass calculation: 0.0420 mol × 44.0 g mol-1 = 1.85 g confirmed.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Answer given to 3 significant figures, limited by the concentration of NaOH (0.150 mol dm-3) which has the fewest significant figures.\"\n  },\n  \"method\": \"First, calculate moles of NaOH used: n(NaOH) = c × V = 0.150 mol dm-3 × (23.40/1000) dm3 = 0.00351 mol. From the balanced equation (L40), 2 moles of NaOH react with 1 mole of H2SO4, so n(H2SO4) = 0.00351 / 2 = 0.001755 mol. Finally, calculate concentration of H2SO4: c = n/V = 0.001755 mol / (25.00/1000) dm3 = 0.001755 / 0.02500 = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"n = c × V\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\"\n  ],\n  \"checks\": [\n    \"Mole ratio from equation: 2 NaOH : 1 H2SO4 correctly applied.\",\n    \"Volume conversions: 23.40 cm3 = 0.02340 dm3 and 25.00 cm3 = 0.02500 dm3.\",\n    \"Final concentration: 0.001755 mol / 0.02500 dm3 = 0.0702 mol dm-3 verified.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"Answer given to 3 significant figures, consistent with the precision of the bond energy values provided (all given to 3 significant figures).\"\n  },\n  \"method\": \"Using deltaH = sum(bonds broken) - sum(bonds formed). For bonds broken in reactants: CH4 has 4 C-H bonds = 4 × 413 = 1652 kJ mol-1; 2O2 has 2 O=O bonds = 2 × 498 = 996 kJ mol-1. Total bonds broken = 1652 + 996 = 2648 kJ mol-1. For bonds formed in products: CO2 has 2 C=O bonds = 2 × 805 = 1610 kJ mol-1; 2H2O has 4 O-H bonds = 4 × 463 = 1852 kJ mol-1. Total bonds formed = 1610 + 1852 = 3462 kJ mol-1. deltaH = 2648 - 3462 = -814 kJ mol-1.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"Bonds broken total: 4(413) + 2(498) = 1652 + 996 = 2648 kJ mol-1 confirmed.\",\n    \"Bonds formed total: 2(805) + 4(463) = 1610 + 1852 = 3462 kJ mol-1 confirmed.\",\n    \"Negative deltaH indicates exothermic reaction, consistent with combustion.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"Answer given to 3 significant figures, limited by the least precise input: current (1.50 A), time (30.0 min), and Faraday constant (96500 C mol-1).\"\n  },\n  \"method\": \"First, convert time to seconds: t = 30.0 min × 60 = 1800 s. Calculate charge using Q = I × t: Q = 1.50 A × 1800 s = 2700 C. Calculate moles of electrons using n(e-) = Q/F: n(e-) = 2700 C / 96500 C mol-1 = 0.0280 mol. From the half-equation, 2 moles of electrons deposit 1 mole of Cu, so n(Cu) = 0.0280 / 2 = 0.0140 mol. Calculate mass: m = n × Ar = 0.0140 mol × 63.55 g mol-1 = 0.889 g.\",\n  \"key_equations\": [\n    \"Q = I × t\",\n    \"n(e-) = Q / F\",\n    \"m = n × Ar\"\n  ],\n  \"line_refs\": [\n    \"L19\",\n    \"L24\",\n    \"L51\",\n    \"L52\"\n  ],\n  \"checks\": [\n    \"Time conversion: 30.0 min × 60 = 1800 s correctly calculated.\",\n    \"Charge calculation: 1.50 A × 1800 s = 2700 C verified.\",\n    \"Stoichiometry: 2 mol e- per 1 mol Cu from half-equation correctly applied.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"dimensionless\",\n    \"precision_note\": \"Answer given to 3 significant figures, consistent with input mole values (0.180 mol and 0.220 mol) and volume (2.00 dm3).\"\n  },\n  \"method\": \"First, calculate equilibrium concentrations: [NO2] = moles/volume = 0.180 mol / 2.00 dm3 = 0.0900 mol dm-3; [N2O4] = 0.220 mol / 2.00 dm3 = 0.110 mol dm-3. Then apply the equilibrium expression Kc = [NO2]^2 / [N2O4]: Kc = (0.0900)^2 / 0.110 = 0.00810 / 0.110 = 0.0736. The result is dimensionless (unitless) as specified in the report instructions.\",\n  \"key_equations\": [\n    \"Kc = [NO2]^2 / [N2O4]\",\n    \"[X] = moles / volume\"\n  ],\n  \"line_refs\": [\n    \"L20\",\n    \"L56\",\n    \"L57\",\n    \"L58\"\n  ],\n  \"checks\": [\n    \"Concentration [NO2] = 0.180 / 2.00 = 0.0900 mol dm-3 correctly calculated.\",\n    \"Concentration [N2O4] = 0.220 / 2.00 = 0.110 mol dm-3 correctly calculated.\",\n    \"Kc calculation: (0.0900)^2 / 0.110 = 0.0736 dimensionless verified.\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 56,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:09:23.111Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:09:25.907Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:09:25.907Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:09:28.058Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:09:28.058Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:09:28.058Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:09:28.058Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:09:28.058Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:09:28.059Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:09:39.981Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:09:42.790Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:09:42.790Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:09:42.790Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:09:42.790Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:09:42.791Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:09:42.791Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:10:40.439Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:10:43.318Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "All six JSON outputs are faithful to the provided report. Each solution uses only the given data and the specified equations/constants (L14–L21, L23–L27), performs correct unit conversions (cm3 to dm3; minutes to seconds), applies correct stoichiometric ratios (L34, L40, L52), and reports numerically correct final answers with reasonable significant-figure handling. No fabricated quantitative claims were introduced. Line references cited are valid and correspond to relevant report lines (e.g., L"
        }
      }
    },
    {
      "model": "gemini-2.5-pro",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-2-5-pro-tumor-vaccine-ici-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": true,
      "graderPass": false,
      "durationMs": 140721,
      "agentCostUsd": 0.102747875,
      "graderCostUsd": 0.020545,
      "totalCostUsd": 0.123292875,
      "agentUsage": {
        "promptTokens": 48732,
        "cachedTokens": 18353,
        "responseTokens": 3029,
        "thinkingTokens": 3219,
        "totalTokens": 54980
      },
      "graderUsage": {
        "promptTokens": 4068,
        "cachedTokens": 0,
        "responseTokens": 548,
        "thinkingTokens": 411,
        "totalTokens": 5027
      },
      "totalUsage": {
        "promptTokens": 52800,
        "cachedTokens": 18353,
        "responseTokens": 3577,
        "thinkingTokens": 3630,
        "totalTokens": 60007
      },
      "modelVersions": [
        "gemini-2.5-pro"
      ],
      "agentFinalText": "I have completed the task and written all the required files.\n\nHere is a checklist of the written output files:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "datasets_or_cohorts.2.description: Too small: expected string to have >=20 characters",
            "datasets_or_cohorts.3.description: Too small: expected string to have >=20 characters",
            "datasets_or_cohorts.4.description: Too small: expected string to have >=20 characters"
          ],
          "content": "{\n    \"paper\": {\n        \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n        \"doi\": \"10.1038/s41586-025-09006-8\",\n        \"publication_year\": 2025,\n        \"domain\": \"oncology-immunology\",\n        \"study_type\": \"preclinical+retrospective\"\n    },\n    \"core_question\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n    \"datasets_or_cohorts\": [\n        {\n            \"id\": \"mouse-efficacy-cohort\",\n            \"label\": \"Mouse efficacy cohort (combination therapy)\",\n            \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n            \"description\": \"78 tumor-bearing mice pooled across repeat experiments.\"\n        },\n        {\n            \"id\": \"mouse-control-cohort\",\n            \"label\": \"Mouse control cohort (vaccine only, ICI only, and vehicle)\",\n            \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n            \"description\": \"84 tumor-bearing mice pooled across matched controls.\"\n        },\n        {\n            \"id\": \"human-retrospective-cohort\",\n            \"label\": \"Human retrospective metastatic cohort\",\n            \"sample_size_or_observations\": \"130 patients total\",\n            \"description\": \"130 patients total.\"\n        },\n        {\n            \"id\": \"human-vaccinated-subgroup\",\n            \"label\": \"Human vaccinated subgroup\",\n            \"sample_size_or_observations\": \"43 patients\",\n            \"description\": \"43 patients.\"\n        },\n        {\n            \"id\": \"human-unvaccinated-subgroup\",\n            \"label\": \"Human unvaccinated subgroup\",\n            \"sample_size_or_observations\": \"87 patients\",\n            \"description\": \"87 patients.\"\n        }\n    ],\n    \"major_limitations\": [\n        \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n        \"Vaccination timing relative to ICI initiation varied across patients.\",\n        \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n        \"Mouse model effects may not map one-to-one to all human tumors.\",\n        \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    ]\n}"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n    \"findings\": [\n        {\n            \"id\": \"Q01\",\n            \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n            \"value\": \"62.3%\",\n            \"comparator_or_baseline\": \"37.3%\",\n            \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n            \"evidence_line_refs\": [\n                \"L28\"\n            ]\n        },\n        {\n            \"id\": \"Q02\",\n            \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n            \"value\": \"40.6%\",\n            \"comparator_or_baseline\": \"20.6%\",\n            \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n            \"evidence_line_refs\": [\n                \"L29\"\n            ]\n        },\n        {\n            \"id\": \"Q03\",\n            \"metric\": \"Retrospective human survival comparison p-value\",\n            \"value\": \"p=0.01\",\n            \"comparator_or_baseline\": \"N/A\",\n            \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n            \"evidence_line_refs\": [\n                \"L30\"\n            ]\n        },\n        {\n            \"id\": \"Q04\",\n            \"metric\": \"Type I interferon response score (normalized units)\",\n            \"value\": \"3.1\",\n            \"comparator_or_baseline\": \"1.0\",\n            \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n            \"evidence_line_refs\": [\n                \"L31\"\n            ]\n        },\n        {\n            \"id\": \"Q05\",\n            \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n            \"value\": \"2.4x\",\n            \"comparator_or_baseline\": \"1.0x\",\n            \"interpretation\": \"Checkpoint axis became more targetable\",\n            \"evidence_line_refs\": [\n                \"L32\"\n            ]\n        },\n        {\n            \"id\": \"Q06\",\n            \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n            \"value\": \"1.8x\",\n            \"comparator_or_baseline\": \"1.0x\",\n            \"interpretation\": \"Increased immune infiltration with combination therapy\",\n            \"evidence_line_refs\": [\n                \"L33\"\n            ]\n        }\n    ],\n    \"controls_or_null_results\": [\n        {\n            \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n            \"evidence_line_ref\": \"L36\"\n        },\n        {\n            \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n            \"evidence_line_ref\": \"L37\"\n        },\n        {\n            \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n            \"evidence_line_ref\": \"L38\"\n        },\n        {\n            \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n            \"evidence_line_ref\": \"L39\"\n        }\n    ]\n}"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n    \"claims\": [\n        {\n            \"claim_id\": \"C01\",\n            \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Marked induction after mRNA vaccination in tumors\",\n                    \"line_ref\": \"L31\"\n                },\n                {\n                    \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n                    \"line_ref\": \"L39\"\n                }\n            ],\n            \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n        },\n        {\n            \"claim_id\": \"C02\",\n            \"claim\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n            \"strength\": \"moderate\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\n                    \"line_ref\": \"L28\"\n                },\n                {\n                    \"quote\": \"Strong expansion of MHC-I-presented landscape\",\n                    \"line_ref\": \"L29\"\n                }\n            ],\n            \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n        },\n        {\n            \"claim_id\": \"C03\",\n            \"claim\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n            \"strength\": \"moderate\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%\",\n                    \"line_ref\": \"L28\"\n                },\n                {\n                    \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\",\n                    \"line_ref\": \"L29\"\n                }\n            ],\n            \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n        },\n        {\n            \"claim_id\": \"C04\",\n            \"claim\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x\",\n                    \"line_ref\": \"L32\"\n                },\n                {\n                    \"quote\": \"Checkpoint axis became more targetable\",\n                    \"line_ref\": \"L32\"\n                }\n            ],\n            \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n        },\n        {\n            \"claim_id\": \"C05\",\n            \"claim\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n                    \"line_ref\": \"L30\"\n                },\n                {\n                    \"quote\": \"Increased immune infiltration with combination therapy\",\n                    \"line_ref\": \"L33\"\n                }\n            ],\n            \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n        }\n    ]\n}"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "glossary.2.definition: Too small: expected string to have >=20 characters"
          ],
          "content": "{\n    \"headline\": \"Injecting mRNA vaccines directly into tumors may boost the effectiveness of cancer immunotherapy.\",\n    \"plain_language_summary\": \"This study explored a new way to make cancer treatments called immune checkpoint inhibitors (ICIs) more effective. ICIs help the immune system fight cancer, but they don't work for everyone. The researchers investigated if injecting an mRNA vaccine directly into a tumor could make it more sensitive to ICIs. They found that in mice, this approach triggered an immune response inside the tumor, making the cancer cells more recognizable to the immune system. This led to better tumor control when combined with an ICI. The study also looked at data from human cancer patients and found that those who had received a SARS-CoV-2 mRNA vaccine seemed to have better outcomes when treated with ICIs. While promising, this was not a controlled study in humans, so more research is needed to confirm these findings.\",\n    \"what_is_new\": [\n        \"Intratumoral mRNA vaccination was shown to increase the number of cancer-related peptides displayed on tumor cells, making them more visible to the immune system.\",\n        \"The study provides evidence that this vaccination strategy can make tumors more susceptible to immune checkpoint blockade, a common type of cancer immunotherapy.\",\n        \"A retrospective analysis of human patients suggested that those who had received a SARS-CoV-2 mRNA vaccine had better survival outcomes when treated with immune checkpoint inhibitors.\"\n    ],\n    \"why_caution_is_needed\": [\n        \"The human data was from a retrospective study, meaning it was not a controlled experiment, and so other factors could have influenced the results.\",\n        \"The positive effects seen in mice might not be the same in humans, as animal models do not perfectly replicate human disease.\",\n        \"The timing and type of mRNA vaccine and cancer immunotherapy varied among the patients in the study, making it difficult to draw firm conclusions.\"\n    ],\n    \"glossary\": [\n        {\n            \"term\": \"Immune checkpoint inhibitors (ICIs)\",\n            \"definition\": \"A type of cancer treatment that helps the immune system recognize and attack cancer cells.\"\n        },\n        {\n            \"term\": \"mRNA vaccine\",\n            \"definition\": \"A vaccine that uses a molecule called messenger RNA (mRNA) to teach the body's cells how to make a protein that triggers an immune response.\"\n        },\n        {\n            \"term\": \"Intratumoral\",\n            \"definition\": \"Inside a tumor.\"\n        },\n        {\n            \"term\": \"PD-L1\",\n            \"definition\": \"A protein that can be found on some cancer cells, which helps them evade the immune system.\"\n        },\n        {\n            \"term\": \"MHC-I\",\n            \"definition\": \"A molecule on the surface of most cells that presents peptides (small pieces of proteins) to the immune system.\"\n        }\n    ],\n    \"open_questions\": [\n        \"Would this approach be effective in a prospective, randomized clinical trial in humans?\",\n        \"What is the optimal timing and dosage for intratumoral mRNA vaccination when combined with immune checkpoint inhibitors?\",\n        \"Could this strategy be applied to other types of cancers and immunotherapies?\"\n    ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 22,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:13.523Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:20.445Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:23.520Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:29.082Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:08:50.016Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:55.212Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:09:05.976Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:09:14.721Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:09:36.301Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:09:40.336Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:10:00.881Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 3,
            "coverage": 4,
            "usefulness": 5
          },
          "critical_issues": [
            "Invalid/insufficient evidence line mapping for key claims in claim_audit.json: Claim C05 asserts that the combination “improves tumor control in mice and aligns with better outcomes in the retrospective human cohort,” but its evidence line refs are L30 (human survival p-value) and L33 (CD8+ T-cell density). Neither L30 nor L33 supports the “improves tumor control in mice” part; the report’s explicit statement about improved mouse tumor control is in the mechanistic chain summary (L46). This violates the requirement that line references be valid and map to the report lines supporting the claim.",
            "Overstated certainty labels in claim_audit.json given the report’s framing: multiple mechanistic steps are tagged as “strong” (e.g., C04, C05) even though the report notes heterogeneity of mechanistic readouts across model systems (L53) and emphasizes that human evidence is retrospective/non-causal (L49–L52, L55–L56). The qualitative “strong” grading is not well-calibrated to the stated caveats.",
            "study_overview.json and public_summary.json are flagged as groundingValid:false/schemaValid:false in the provided validation results, and the content issues reflect that: several cohort descriptions are too minimal (“43 patients.” / “87 patients.”), reducing downstream utility for review and cohort interpretation (even if numerically consistent with L21–L23).",
            "Public-facing statements sometimes imply broader efficacy than supported: public_summary.json says the approach “led to better tumor control when combined with an ICI” without explicitly reminding readers that vaccine-only and ICI-only had limited/did-not-durably-control outcomes in certain models (L36–L37) and that mechanistic effects were not uniform across settings (L53). This is partly mitigated by the caution section, but the main summary could be misread as more general than the report supports."
          ],
          "summary": "The JSON outputs largely reproduce the report’s listed quantitative values correctly (e.g., immunopeptidome fractions, p=0.01, IFN score, PD-L1 fold-change, CD8 density; L28–L33) and include the main high-level caveats about retrospective human analysis and translational limits (L49–L53, L55–L56). However, the submission fails strict grading because at least one core synthesized claim (claim_audit C05) is not properly grounded by its cited line references (mouse tumor control is not supported by"
        }
      }
    },
    {
      "model": "gemini-2.5-pro",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-2-5-pro-gcse-chemistry-8-9-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 283212,
      "agentCostUsd": 0.128481125,
      "graderCostUsd": 0.014041999999999999,
      "totalCostUsd": 0.142523125,
      "agentUsage": {
        "promptTokens": 86247,
        "cachedTokens": 59589,
        "responseTokens": 2898,
        "thinkingTokens": 5873,
        "totalTokens": 95018
      },
      "graderUsage": {
        "promptTokens": 3776,
        "cachedTokens": 0,
        "responseTokens": 173,
        "thinkingTokens": 358,
        "totalTokens": 4307
      },
      "totalUsage": {
        "promptTokens": 90023,
        "cachedTokens": 59589,
        "responseTokens": 3071,
        "thinkingTokens": 6231,
        "totalTokens": 99325
      },
      "modelVersions": [
        "gemini-2.5-pro"
      ],
      "agentFinalText": "I have completed the task. Here is a checklist of the written output files:\n\n- `output/problem_01.json`\n- `output/problem_02.json`\n- `output/problem_03.json`\n- `output/problem_04.json`\n- `output/problem_05.json`\n- `output/problem_06.json`",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.0200,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"The result is given to 3 significant figures, consistent with the input concentration (0.200 mol dm-3) and volumes (25.0 cm3, 250.0 cm3), all of which are given to 3 s.f.\"\n  },\n  \"method\": \"The problem is a straightforward dilution calculation. Using the dilution formula c1V1 = c2V2, the final concentration (c2) is found by rearranging to c2 = c1 * (V1 / V2). The initial concentration (c1) is 0.200 mol dm-3 and the initial volume (V1) is 25.0 cm3. The final diluted volume (V2) is 250.0 cm3. Substituting these values gives c2 = 0.200 * (25.0 / 250.0) = 0.0200 mol dm-3. The units of volume cancel out, so no conversion to dm3 is required for the ratio.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\"\n  ],\n  \"checks\": [\n    \"The final concentration is 1/10th of the initial concentration, which is expected as the volume was increased by a factor of 10.\",\n    \"Units are correct (mol dm-3).\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"The result is given to 3 significant figures, determined by the least precise input values (sample mass and purity percentage), which have 3 s.f.\"\n  },\n  \"method\": \"First, the mass of pure CaCO3 in the limestone sample is calculated by multiplying the total mass (5.00 g) by the purity percentage (84.0%), yielding 4.20 g of CaCO3. Then, the moles of CaCO3 are determined using the formula n = m / Mr, with m = 4.20 g and Mr(CaCO3) = 100.1 g/mol. This gives 0.04196 mol of CaCO3. According to the 1:1 stoichiometric ratio in the reaction CaCO3 + 2HCl -> CaCl2 + CO2 + H2O, the moles of CO2 produced are equal to the moles of CaCO3. Finally, the mass of CO2 is calculated by multiplying the moles of CO2 by its molar mass (Mr = 44.0 g/mol), resulting in a final mass of 1.85 g.\",\n  \"key_equations\": [\n    \"n = m / Mr\",\n    \"CaCO3 + 2HCl -> CaCl2 + CO2 + H2O\"\n  ],\n  \"line_refs\": [\n    \"L14\",\n    \"L25\",\n    \"L33\",\n    \"L34\"\n  ],\n  \"checks\": [\n    \"The mass of CO2 is less than the mass of CaCO3 used, which is chemically sensible.\",\n    \"All steps are followed logically, from purity calculation to stoichiometric conversion and final mass calculation.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"The result is given to 3 significant figures, determined by the concentration of NaOH (0.150 mol dm-3), which is the input value with the fewest significant figures.\"\n  },\n  \"method\": \"First, the moles of NaOH used in the titration are calculated using the formula n = c * V. The volume of NaOH is converted from cm3 to dm3 (23.40 cm3 = 0.02340 dm3). Moles of NaOH = 0.150 mol dm-3 * 0.02340 dm3 = 0.00351 mol. From the reaction stoichiometry (H2SO4 + 2NaOH -> Na2SO4 + 2H2O), the molar ratio of H2SO4 to NaOH is 1:2. Therefore, the moles of H2SO4 are half the moles of NaOH: 0.00351 mol / 2 = 0.001755 mol. Finally, the concentration of H2SO4 is calculated by dividing the moles of H2SO4 by its volume in dm3 (25.00 cm3 = 0.02500 dm3), which gives 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"H2SO4 + 2NaOH -> Na2SO4 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\"\n  ],\n  \"checks\": [\n    \"The volumes were correctly converted from cm3 to dm3 for the mole calculations.\",\n    \"The stoichiometric ratio of 1:2 between H2SO4 and NaOH was correctly applied.\",\n    \"Final concentration is of a reasonable order of magnitude for a titration.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"The result is an integer value as all input bond energies are integers. The precision is determined by the given bond energy values.\"\n  },\n  \"method\": \"The enthalpy change of reaction is calculated using the formula: deltaH = sum(energy of bonds broken) - sum(energy of bonds formed). First, identify the bonds broken in the reactants (CH4 and 2O2): four C-H bonds and two O=O bonds. The energy input to break these is (4 * 413) + (2 * 498) = 1652 + 996 = 2648 kJ/mol. Next, identify the bonds formed in the products (CO2 and 2H2O): two C=O bonds and four O-H bonds. The energy released in forming these is (2 * 805) + (4 * 463) = 1610 + 1852 = 3462 kJ/mol. Finally, deltaH = 2648 - 3462 = -814 kJ/mol.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\",\n    \"CH4 + 2O2 -> CO2 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"The calculation correctly identifies all bonds broken and formed in the balanced equation.\",\n    \"The final answer is negative, which is expected for a combustion reaction (exothermic).\",\n    \"The stoichiometric coefficients from the balanced equation are correctly applied to the number of molecules and thus bonds.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"The result is given to 3 significant figures, consistent with the input current (1.50 A) and time (30.0 min).\"\n  },\n  \"method\": \"First, the total electrical charge (Q) passed is calculated using the formula Q = I * t. The time is converted from minutes to seconds (30.0 min * 60 = 1800 s). Q = 1.50 A * 1800 s = 2700 C. Next, the moles of electrons are found by dividing the charge by the Faraday constant (F): n(e-) = Q / F = 2700 C / 96500 C mol-1 = 0.02798 mol. The cathode half-equation Cu2+ + 2e- -> Cu shows a 2:1 molar ratio between electrons and copper. Thus, moles of Cu = 0.02798 / 2 = 0.01399 mol. Finally, the mass of copper deposited is calculated by multiplying the moles of Cu by its atomic mass (63.55 g/mol), which gives 0.889 g.\",\n  \"key_equations\": [\n    \"Q = I * t\",\n    \"n(e-) = Q / F\",\n    \"Cu2+ + 2e- -> Cu\",\n    \"n = m / Mr\"\n  ],\n  \"line_refs\": [\n    \"L17\",\n    \"L18\",\n    \"L51\",\n    \"L52\"\n  ],\n  \"checks\": [\n    \"Time was correctly converted to seconds.\",\n    \"The stoichiometric ratio from the half-equation was correctly used.\",\n    \"The final mass is a reasonable value for a laboratory-scale electrolysis experiment.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"dimensionless\",\n    \"precision_note\": \"The result is given to 3 significant figures, consistent with the input mole and volume data.\"\n  },\n  \"method\": \"The equilibrium constant, Kc, is calculated using the expression Kc = [NO2]^2 / [N2O4]. First, the concentrations of NO2 and N2O4 at equilibrium are determined by dividing their molar amounts by the vessel volume (2.00 dm3). This gives [NO2] = 0.180 mol / 2.00 dm3 = 0.0900 mol dm-3 and [N2O4] = 0.220 mol / 2.00 dm3 = 0.110 mol dm-3. These concentration values are then substituted into the Kc expression: Kc = (0.0900)^2 / 0.110 = 0.0081 / 0.110 = 0.0736. As per the instructions, Kc is reported as a dimensionless value.\",\n  \"key_equations\": [\n    \"Kc = [NO2]^2 / [N2O4]\",\n    \"c = n / V\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L20\",\n    \"L57\",\n    \"L58\"\n  ],\n  \"checks\": [\n    \"The concentrations were correctly calculated before being used in the Kc expression.\",\n    \"The stoichiometry from the balanced equation (the power of 2 for NO2) was correctly applied.\",\n    \"The final answer is correctly reported as dimensionless.\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 32,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 12,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 13,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 14,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 15,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 16,
            "toolName": "list_directory"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:10:34.289Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:10:44.365Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:10:50.627Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:11:07.821Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:11:23.082Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:11:33.196Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:11:51.063Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:11:57.696Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:12:15.787Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:12:23.027Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:13:20.294Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:13:26.739Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:13:40.249Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:14:22.805Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:14:52.660Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:14:55.201Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "All six JSON outputs are consistent with the provided report data/equations and do not introduce unsupported quantitative claims. Calculations for dilution (P01), purity/stoichiometry (P02), titration stoichiometry and concentration (P03), bond-enthalpy estimate (P04), electrolysis via Faraday’s laws (P05), and equilibrium constant Kc from equilibrium concentrations (P06) are numerically correct and appropriately sign/units calibrated (including Kc reported as dimensionless per L21). Line_refs,虽"
        }
      }
    },
    {
      "model": "gemini-flash-latest",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-flash-latest-tumor-vaccine-ici-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": true,
      "graderPass": false,
      "durationMs": 134546,
      "agentCostUsd": 0,
      "graderCostUsd": 0.01962975,
      "totalCostUsd": 0.01962975,
      "agentUsage": {
        "promptTokens": 49218,
        "cachedTokens": 27971,
        "responseTokens": 3570,
        "thinkingTokens": 4999,
        "totalTokens": 57787
      },
      "graderUsage": {
        "promptTokens": 4545,
        "cachedTokens": 0,
        "responseTokens": 489,
        "thinkingTokens": 345,
        "totalTokens": 5379
      },
      "totalUsage": {
        "promptTokens": 53763,
        "cachedTokens": 27971,
        "responseTokens": 4059,
        "thinkingTokens": 5344,
        "totalTokens": 63166
      },
      "modelVersions": [
        "gemini-flash-latest"
      ],
      "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"mixed\"\n  },\n  \"core_question\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse Efficacy\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving intratumoral mRNA vaccine and anti-PD-L1 combinations.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse Control\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls receiving vaccine only, ICI only, or vehicle treatments.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human Retrospective\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Total metastatic patients receiving ICI treatment, retrospectively analyzed based on prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human Vaccinated\",\n      \"sample_size_or_observations\": \"43\",\n      \"description\": \"Metastatic patients from the retrospective cohort who had received prior SARS-CoV-2 mRNA vaccination.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human Unvaccinated\",\n      \"sample_size_or_observations\": \"87\",\n      \"description\": \"Metastatic patients from the retrospective cohort who had not received prior SARS-CoV-2 mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score\",\n      \"value\": \"3.1 normalized units\",\n      \"comparator_or_baseline\": \"1.0 normalized units\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x fold-change\",\n      \"comparator_or_baseline\": \"1.0x fold-change\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x fold-change\",\n      \"comparator_or_baseline\": \"1.0x fold-change\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination significantly broadens the repertoire of tumor antigens presented by MHC-I molecules.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"The increased antigen presentation is linked to type I interferon signaling, which can be experimentally blocked, eliminating the benefit.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination sensitizes previously non-responsive tumors to the therapeutic effects of immune checkpoint blockade (ICI).\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        }\n      ],\n      \"caveat\": \"The observed human benefit comes from a retrospective, non-randomized cohort analysis, meaning residual confounding cannot be ruled out and direct causal interpretation is limited.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The sensitization effect is mechanistically dependent on the induction of Type I interferon signaling within the tumor microenvironment.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The study noted that lipid particle controls lacking the mRNA sequence failed to reproduce the sensitization, indicating the payload is essential for this pathway activation.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The combined therapy increases tumor targetability by upregulating PD-L1 expression and enhancing CD8+ T-cell infiltration in the tumor.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Despite these favorable changes, ICI-only treatment still showed limited activity in low-immunogenic settings, suggesting the combination effect is synergistic rather than purely additive.\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "headline: Too big: expected string to have <=120 characters",
            "plain_language_summary: Too big: expected string to have <=1200 characters"
          ],
          "content": "{\n  \"headline\": \"mRNA Vaccines Prime Tumors for Stronger Immune Checkpoint Blockade Response in Preclinical Models and Retrospective Human Data\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) are powerful cancer drugs, but they often fail when tumors are 'invisible' to the immune system. This study, primarily conducted in mice, shows that injecting an mRNA vaccine directly into a tumor can dramatically increase its visibility and vulnerability. The vaccine triggers a local inflammatory response, specifically by inducing Type I interferon signaling (L42), which acts like an 'alert' system. This alert system forces the tumor cells to display a wider range of protein fragments (antigens) on their surface (L28, L29), making them a much easier target for T-cells. Furthermore, the combination therapy increases key immune markers like PD-L1 (L32) and CD8+ T-cell infiltration (L33). In a small, retrospective analysis of human cancer patients, those who had previously received the SARS-CoV-2 mRNA vaccine while on ICI therapy showed better survival (p=0.01), aligning with the mouse results (L30). The overall finding is that the mRNA vaccine acts as a powerful 'sensitizer' for ICI, allowing the immune system to finally recognize and attack the cancer. However, this promising finding is currently limited by the fact that the human data is not from a controlled clinical trial and prospective studies are urgently required to confirm this approach (L49, L56).\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA delivery successfully triggers a Type I interferon-rich inflammatory state in tumors, a key event for local immune activation.\",\n    \"The interferon signaling pathway mechanistically links mRNA vaccination to a strong expansion of the tumor's MHC-I presented antigen landscape, improving T-cell recognition.\",\n    \"Retrospective analysis suggests that prior SARS-CoV-2 mRNA vaccination may sensitize metastatic tumors to immune checkpoint blockade, potentially improving patient outcomes (L30).\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The positive human survival data comes from a retrospective, non-randomized study, meaning the results could be due to unmeasured confounding factors (L49).\",\n    \"The study is primarily based on mouse models, and the observed effects may not translate directly or uniformly to all types of human tumors (L52, L53).\",\n    \"The therapeutic benefit relies on the Type I interferon signaling pathway, and experimental blockade of this pathway eliminated the sensitization effect (L39).\",\n    \"Vaccination timing relative to ICI initiation varied across patients in the human cohort, which limits the ability to define an optimal treatment protocol (L50).\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI\",\n      \"definition\": \"Immune Checkpoint Inhibitor: A type of drug that blocks checkpoint proteins (like PD-L1) on immune cells or cancer cells, effectively 'releasing the brakes' on the immune system so it can attack cancer.\"\n    },\n    {\n      \"term\": \"Antigen presentation\",\n      \"definition\": \"The process by which tumor cells display small fragments of their internal proteins on their surface via MHC molecules, allowing immune T-cells to check if the cell is healthy or cancerous.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"Messenger RNA vaccine: A type of vaccine that contains genetic instructions (mRNA) to temporarily produce a specific protein inside the body's cells to stimulate a robust immune response.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A type of signaling molecule released by cells in response to immune activation, which triggers a powerful inflammatory and anti-cancer immune state, crucial for the observed sensitization.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"Programmed Death-Ligand 1: A protein often expressed on cancer cells that helps them evade immune detection by binding to the PD-1 receptor on T-cells, which deactivates the T-cell.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will a prospective, randomized clinical trial confirm the observed survival benefit of combining mRNA vaccination with ICI therapy in metastatic cancer patients?\",\n    \"What is the optimal delivery route and timing for the mRNA vaccine administration relative to the initiation of immune checkpoint blockade for maximum efficacy?\",\n    \"Is the sensitization effect generalizable across different cancer types, or is it restricted to tumors with a certain baseline immunogenic or inflammatory profile?\",\n    \"Can the observed mechanistic changes, like PD-L1 upregulation, be used as predictive biomarkers to select patients who will most benefit from this combination therapy?\",\n    \"Can the intratumoral delivery method be scaled and safely applied in a clinical setting across various tumor sites?\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 22,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:12.698Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:15.922Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:08:21.061Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:08:26.371Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:08:31.724Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:08:52.473Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:08:55.824Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:09:05.898Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:09:11.994Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:09:21.582Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:09:45.638Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 5,
            "coverage": 2,
            "usefulness": 4
          },
          "critical_issues": [
            "public_summary.json is explicitly schema-invalid (headline and plain_language_summary exceed allowed lengths) and marked groundingValid:false. This fails the requirement that outputs be coherent and useful for downstream review.",
            "public_summary.json contains overstated language not supported by the report’s calibrated phrasing, e.g., it says intratumoral mRNA vaccination can \"dramatically increase\" tumor visibility/vulnerability and calls it a \"powerful 'sensitizer'\" in a way that is stronger than the report’s more cautious framing (compare L55–L56).",
            "claim_audit.json uses overconfident/unsupported statistical phrasing: C01 states \"significantly broadens\" antigen repertoire, but the report provides descriptive percentages (L28–L29) without statistical testing or significance claims; this is an overstatement under the grading rules.",
            "claim_audit.json assigns 'strong' strength labels in places where the report is mechanistic/hypothesis-driven and/or model-dependent (L53), and where the translational evidence is retrospective and non-causal (L49–L51). While some caveats are mentioned, the strength labels remain too assertive given the evidence level.",
            "Some important caveat-to-claim linkages are not tightly grounded with line references in the JSON fields that introduce new statements (e.g., caveat text referencing lipid-particle controls in C03 is consistent with L38 but is not line-referenced there; grading requires line references to be valid and map to the report lines for claims being made)."
          ],
          "summary": "The overview and quantitative_findings files largely mirror the report’s cohorts, numbers, and line-referenced quantitative metrics (L19–L33, L36–L39). However, the submission fails overall because public_summary.json is schema-invalid and flagged as not grounded, making it unreliable for downstream use. In addition, the narrative and claim_audit contain overstatements (e.g., \"significantly,\" \"dramatically,\" and 'strong' claim strength) that are not justified by the report’s provided evidence (L"
        }
      }
    },
    {
      "model": "gemini-flash-latest",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-flash-latest-gcse-chemistry-8-9-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": true,
      "graderPass": false,
      "durationMs": 189608,
      "agentCostUsd": 0,
      "graderCostUsd": 0.013254499999999999,
      "totalCostUsd": 0.013254499999999999,
      "agentUsage": {
        "promptTokens": 77031,
        "cachedTokens": 54519,
        "responseTokens": 3281,
        "thinkingTokens": 9534,
        "totalTokens": 89846
      },
      "graderUsage": {
        "promptTokens": 3990,
        "cachedTokens": 0,
        "responseTokens": 331,
        "thinkingTokens": 117,
        "totalTokens": 4438
      },
      "totalUsage": {
        "promptTokens": 81021,
        "cachedTokens": 54519,
        "responseTokens": 3612,
        "thinkingTokens": 9651,
        "totalTokens": 94284
      },
      "modelVersions": [
        "gemini-flash-latest"
      ],
      "agentFinalText": "The task is complete. The required JSON files have been generated, extracting and summarizing the quantitative problems from the report.\n\nChecklist of written output files:\n- `output/problem_01.json`\n- `output/problem_02.json`\n- `output/problem_03.json`\n- `output/problem_04.json`\n- `output/problem_05.json`\n- `output/problem_06.json`",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.0200,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"The concentration and volumes are given to three significant figures, so the final concentration is reported to three significant figures.\"\n  },\n  \"method\": \"The dilution formula c1V1 = c2V2 is used to find the final concentration (c2). We rearrange the formula to c2 = (c1V1) / V2. Using the given values: c2 = (0.200 mol dm-3 * 25.0 cm3) / 250.0 cm3. The volumes are in the same unit (cm3) so conversion to dm3 is not necessary for the ratio. c2 = 0.0200 mol dm-3.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\",\n    \"L30\"\n  ],\n  \"checks\": [\n    \"The dilution factor is V2/V1 = 250.0 cm3 / 25.0 cm3 = 10.0.\",\n    \"The final concentration is c1 / 10.0 = 0.200 mol dm-3 / 10.0 = 0.0200 mol dm-3. The calculation is confirmed.\",\n    \"The final concentration (0.0200) is less than the initial concentration (0.200), as expected for a dilution.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"The least number of significant figures in the input data is three (5.00 g, 84.0%, 44.0 g mol-1), so the answer is reported to three significant figures.\"\n  },\n  \"method\": \"First, calculate the mass of pure CaCO3 in the sample: Mass(CaCO3) = 5.00 g * 0.840 = 4.20 g. Next, calculate the moles of CaCO3 using n = m / Mr: n(CaCO3) = 4.20 g / 100.1 g mol-1 = 0.041958 mol. Based on the reaction (CaCO3 + 2HCl -> CaCl2 + CO2 + H2O), the mole ratio of CaCO3 to CO2 is 1:1, so n(CO2) = 0.041958 mol. Finally, calculate the mass of CO2 produced using m = n * Mr: Mass(CO2) = 0.041958 mol * 44.0 g mol-1 = 1.846 g. Rounding to three significant figures gives 1.85 g.\",\n  \"key_equations\": [\n    \"n = m / Mr\",\n    \"CaCO3 + 2HCl -> CaCl2 + CO2 + H2O\"\n  ],\n  \"line_refs\": [\n    \"L14\",\n    \"L25\",\n    \"L26\",\n    \"L33\"\n  ],\n  \"checks\": [\n    \"Mass of pure CaCO3 = 5.00 * 0.840 = 4.20 g.\",\n    \"Moles of CaCO3 = 4.20 / 100.1 \\u2248 0.04196 mol.\",\n    \"Maximum mass of CO2 = 0.04196 mol * 44.0 g mol-1 \\u2248 1.846 g, which rounds to 1.85 g.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"The concentration of NaOH (0.150 mol dm-3) has three significant figures, which is the least precise value, so the answer is reported to three significant figures.\"\n  },\n  \"method\": \"First, calculate the moles of the titrant, NaOH, using n = cV. n(NaOH) = 0.150 mol dm-3 * (23.40 / 1000) dm3 = 0.00351 mol. Next, use the stoichiometry from the balanced equation (H2SO4 + 2NaOH -> Na2SO4 + 2H2O) to find the moles of H2SO4. The mole ratio is 1:2 (H2SO4:NaOH), so n(H2SO4) = n(NaOH) / 2 = 0.00351 mol / 2 = 0.001755 mol. Finally, calculate the concentration of H2SO4 using c = n/V: c(H2SO4) = 0.001755 mol / (25.00 / 1000) dm3 = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"H2SO4 + 2NaOH -> Na2SO4 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\",\n    \"L41\"\n  ],\n  \"checks\": [\n    \"Moles of NaOH = 0.150 * 0.02340 dm3 = 0.00351 mol.\",\n    \"Moles of H2SO4 = 0.00351 mol / 2 = 0.001755 mol.\",\n    \"Concentration of H2SO4 = 0.001755 mol / 0.02500 dm3 = 0.0702 mol dm-3. Confirmed.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"All mean bond energy values are given to three significant figures, so the final estimated enthalpy change is reported to three significant figures.\"\n  },\n  \"method\": \"The enthalpy change ($\\u0394$H) is estimated using the formula: \\u0394H = sum(bonds broken) - sum(bonds formed). Bonds broken (reactants): 4 (C-H) + 2 (O=O) = 4(413) + 2(498) = 1652 + 996 = 2648 kJ mol-1. Bonds formed (products): 2 (C=O) + 4 (O-H) = 2(805) + 4(463) = 1610 + 1852 = 3462 kJ mol-1. The estimated enthalpy change is \\u0394H = 2648 - 3462 = -814 kJ mol-1.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\",\n    \"CH4 + 2O2 -> CO2 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"Energy absorbed (bonds broken) = 2648 kJ mol-1.\",\n    \"Energy released (bonds formed) = 3462 kJ mol-1.\",\n    \"The negative result (-814 kJ mol-1) correctly indicates an exothermic reaction, as expected for combustion.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"The current (1.50 A) and time (30.0 min) both have three significant figures, which dictates the precision of the final answer.\"\n  },\n  \"method\": \"First, the time is converted to seconds: 30.0 min * 60 s/min = 1800 s. The total charge (Q) passed is calculated using Faraday's first law, Q = I * t: Q = 1.50 A * 1800 s = 2700 C. The moles of electrons ($n_{e-}$) are calculated using the Faraday constant (F): $n_{e-} = Q / F = 2700 C / 96500 C mol^{-1} = 0.027979 mol$. From the half-equation ($Cu^{2+} + 2e^- -> Cu$), the mole ratio is $2 \\text{ mol } e^- : 1 \\text{ mol } Cu$, so $n_{Cu} = n_{e-} / 2 = 0.0139895 mol$. Finally, the mass is calculated: $m = n \\times Mr = 0.0139895 mol \\times 63.55 g mol^{-1} = 0.88914 g$. Rounded to three significant figures, the mass is 0.889 g.\",\n  \"key_equations\": [\n    \"Q = I * t\",\n    \"n(e-) = Q / F\",\n    \"Cu2+ + 2e- -> Cu\",\n    \"n = m / Mr\"\n  ],\n  \"line_refs\": [\n    \"L17\",\n    \"L19\",\n    \"L24\",\n    \"L51\"\n  ],\n  \"checks\": [\n    \"Total charge Q = 2700 C.\",\n    \"Moles of electrons = 2700 / 96500 \\u2248 0.02798 mol.\",\n    \"Moles of Cu = 0.02798 / 2 \\u2248 0.01399 mol.\",\n    \"Mass of Cu = 0.01399 * 63.55 \\u2248 0.889 g. Confirmed.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": false,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "Invalid JSON: Bad escaped character in JSON at position 676 (line 8 column 418)"
          ],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"unitless\",\n    \"precision_note\": \"All input values (moles and volume) are given to three significant figures, so the result for Kc is reported to three significant figures.\"\n  },\n  \"method\": \"First, the concentrations of the species at equilibrium are calculated using c = n / V. $[NO_2] = 0.180 \\text{ mol} / 2.00 \\text{ dm}^3 = 0.0900 \\text{ mol dm}^{-3}$. $[N_2O_4] = 0.220 \\text{ mol} / 2.00 \\text{ dm}^3 = 0.110 \\text{ mol dm}^{-3}$. Next, the concentrations are substituted into the equilibrium constant expression, $K_c = [NO_2]^2 / [N_2O_4]$. $K_c = (0.0900)^2 / 0.110 = 0.00810 / 0.110 \\approx 0.0736$. The instruction specifies to report $K_c$ as dimensionless.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"Kc = [NO2]^2 / [N2O4]\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L20\",\n    \"L56\",\n    \"L57\"\n  ],\n  \"checks\": [\n    \"[NO2] = 0.0900 mol dm-3.\",\n    \"[N2O4] = 0.110 mol dm-3.\",\n    \"Kc = (0.0900)^2 / 0.110 \\u2248 0.0736. Confirmed.\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 28,
        "failedCalls": 0,
        "toolsUsed": [
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 12,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 13,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 14,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:10:26.653Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:10:29.167Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:10:32.148Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:11:03.052Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:11:11.880Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:11:30.378Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:11:37.421Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:11:46.664Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:11:55.077Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:12:00.942Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:12:08.705Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:12:21.725Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:12:27.476Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:12:36.866Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 4,
            "coverage": 5,
            "usefulness": 4
          },
          "critical_issues": [
            "output/problem_06.json is invalid JSON (explicitly flagged: jsonValid=false; bad escaped character). This makes the set not practically usable for downstream automated review despite the chemistry being broadly correct.",
            "output/problem_06.json is also flagged as groundingValid=false/schemaValid=false, so it fails the requirement that outputs be coherent and useful with valid line references mapped to the report.",
            "Several outputs use report content without citing the most relevant supporting lines in their line_refs, weakening traceability. Examples: P02 relies on the reaction stoichiometry but does not reference the reaction line (L34). P05 relies on the Cu2+ + 2e- -> Cu half-equation but does not reference L52. These are not numerical hallucinations, but they violate the 'line references are valid and map to the numbered report lines' expectation for auditable grounding."
          ],
          "summary": "Most computed answers (P01–P05) are numerically consistent with the given data and equations in the report and are reasonably calibrated. However, the submission fails overall because P06 is not valid JSON and is explicitly marked invalid against JSON/schema/grounding checks, making it unusable in practice. Additionally, some items have incomplete line referencing for key claims (e.g., reaction/half-equation lines), reducing auditability."
        }
      }
    },
    {
      "model": "gemini-3-pro-preview",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-3-pro-preview-tumor-vaccine-ici-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 391663,
      "agentCostUsd": 0.153391,
      "graderCostUsd": 0.01104075,
      "totalCostUsd": 0.16443175,
      "agentUsage": {
        "promptTokens": 54227,
        "cachedTokens": 34535,
        "responseTokens": 2695,
        "thinkingTokens": 6230,
        "totalTokens": 63152
      },
      "graderUsage": {
        "promptTokens": 3653,
        "cachedTokens": 0,
        "responseTokens": 177,
        "thinkingTokens": 155,
        "totalTokens": 3985
      },
      "totalUsage": {
        "promptTokens": 57880,
        "cachedTokens": 34535,
        "responseTokens": 2872,
        "thinkingTokens": 6385,
        "totalTokens": 67137
      },
      "modelVersions": [
        "gemini-3-pro-preview"
      ],
      "agentFinalText": "The following output files have been written:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral mRNA vaccine delivery create an interferon-rich state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse Efficacy Cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving intratumoral mRNA vaccine and anti-PD-L1 combinations.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse Control Cohort\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls receiving vaccine only, ICI only, or vehicle.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human Retrospective Cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The vaccination leads to broader antigen peptide presentation on MHC-I.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD-L1 pathway activity increases following vaccination, justifying combination therapy.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combination of mRNA vaccine and ICI improves tumor control compared to monotherapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    }\n  ]\n}"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"headline\": \"mRNA Vaccines May Help Immunotherapy Work Better Against Resistant Tumors\",\n  \"plain_language_summary\": \"Some cancer treatments, known as immune checkpoint inhibitors, work by unleashing the body's immune system to attack cancer cells. However, these treatments often fail when tumors are \\\"invisible\\\" to the immune system. A new study suggests that injecting COVID-19-style mRNA vaccines directly into tumors can help. In mice, this vaccination triggered a strong alarm signal (interferon response) that made the tumors display more of their proteins on their surface, effectively making them visible to immune cells. When followed by standard immunotherapy, the combination controlled tumors much better than either treatment alone. The researchers also looked at past data from human patients and found that those who had received SARS-CoV-2 mRNA vaccines seemed to respond better to immunotherapy. While promising, more research is needed to prove this works as a deliberate cancer therapy in humans.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination creates an interferon-rich state that makes tumors more visible to the immune system.\",\n    \"The combination of mRNA vaccine and anti-PD-L1 therapy showed improved tumor control in mouse models.\",\n    \"Retrospective human data suggests a link between prior mRNA vaccination and better outcomes with checkpoint blockade.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is based on looking back at past records, which can have hidden biases compared to a controlled trial.\",\n    \"The timing of vaccination relative to cancer treatment varied widely among the patients studied.\",\n    \"Success in mouse models does not always guarantee that the same approach will work effectively in human cancer patients.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitors\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that stop immune responses.\"\n    },\n    {\n      \"term\": \"Intratumoral Delivery\",\n      \"definition\": \"A method of administering a drug or vaccine by injecting it directly into the tumor mass.\"\n    },\n    {\n      \"term\": \"Interferon\",\n      \"definition\": \"A signaling protein released by cells in response to viruses that heightens the anti-viral defenses of nearby cells.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on the cell surface that displays protein fragments to immune cells, allowing them to detect infection or mutation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will the sensitization effect persist in a prospective randomized clinical trial with controlled timing?\",\n    \"Can this approach be effective across different types of solid tumors beyond those tested in the mouse models?\",\n    \"What is the optimal dosage and schedule for administering the mRNA vaccine relative to the checkpoint inhibitor?\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 24,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 12,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:08:18.898Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:08:52.681Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:09:00.333Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:09:36.869Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/quantitative_findings.schema.json",
            "timestamp": "2026-02-12T17:10:06.572Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/claim_audit.schema.json",
            "timestamp": "2026-02-12T17:10:27.934Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/public_summary.schema.json",
            "timestamp": "2026-02-12T17:10:38.450Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "output",
            "timestamp": "2026-02-12T17:11:42.833Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/study_overview.json",
            "timestamp": "2026-02-12T17:12:03.806Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/quantitative_findings.json",
            "timestamp": "2026-02-12T17:12:17.413Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/claim_audit.json",
            "timestamp": "2026-02-12T17:12:31.339Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/public_summary.json",
            "timestamp": "2026-02-12T17:14:16.810Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "The JSON outputs are faithful to the provided report and practically useful. Quantitative values (immunopeptidome fractions, MHC-I peptidome fractions, p-value, interferon score, PD-L1 fold-change, CD8 density fold-change) match the report exactly and are correctly referenced to valid line numbers (L28–L33). Key controls/null results and the central mechanistic chain are represented without introducing new numbers or unsupported causal claims (controls: L36–L39; mechanism: L42–L46). Major caveატ"
        }
      }
    },
    {
      "model": "gemini-3-pro-preview",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-3-pro-preview-gcse-chemistry-8-9-run-1",
      "success": true,
      "schemaPass": true,
      "toolTracePass": true,
      "graderPass": true,
      "durationMs": 513528,
      "agentCostUsd": 0.2157198,
      "graderCostUsd": 0.0164745,
      "totalCostUsd": 0.2321943,
      "agentUsage": {
        "promptTokens": 75843,
        "cachedTokens": 50419,
        "responseTokens": 2809,
        "thinkingTokens": 10090,
        "totalTokens": 88742
      },
      "graderUsage": {
        "promptTokens": 3518,
        "cachedTokens": 0,
        "responseTokens": 195,
        "thinkingTokens": 542,
        "totalTokens": 4255
      },
      "totalUsage": {
        "promptTokens": 79361,
        "cachedTokens": 50419,
        "responseTokens": 3004,
        "thinkingTokens": 10632,
        "totalTokens": 92997
      },
      "modelVersions": [
        "gemini-3-pro-preview"
      ],
      "agentFinalText": "I have completed the task. All required JSON output files have been generated based on `input/report.md` and the provided schemas.\n\n**Written Output Files:**\n- `output/problem_01.json`\n- `output/problem_02.json`\n- `output/problem_03.json`\n- `output/problem_04.json`\n- `output/problem_05.json`\n- `output/problem_06.json`",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P01\",\n  \"final_answer\": {\n    \"value\": 0.02,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Inputs given to 3 and 4 significant figures. The lowest precision is 3 significant figures, so the answer is reported to 3 significant figures (0.0200).\"\n  },\n  \"method\": \"Using the dilution formula c1V1 = c2V2, we identify c1 = 0.200 mol dm-3, V1 = 25.0 cm3, and V2 = 250.0 cm3. Rearranging for c2 gives c2 = (c1 * V1) / V2. Substituting the values: c2 = (0.200 * 25.0) / 250.0 = 5.0 / 250.0 = 0.0200 mol dm-3.\",\n  \"key_equations\": [\n    \"c1V1 = c2V2\"\n  ],\n  \"line_refs\": [\n    \"L16\",\n    \"L29\"\n  ],\n  \"checks\": [\n    \"The volume increased by a factor of 10, so concentration should decrease by a factor of 10.\",\n    \"0.200 / 10 = 0.0200, which matches calculation.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P02\",\n  \"final_answer\": {\n    \"value\": 1.85,\n    \"units\": \"g\",\n    \"precision_note\": \"Mass given to 3 s.f., purity to 3 s.f., atomic masses to 3/4 s.f. Result reported to 3 significant figures.\"\n  },\n  \"method\": \"First, calculate the mass of pure CaCO3 in the sample: 5.00 g * 0.840 = 4.20 g. Using atomic masses from the data (Ca=40.1, C=12.0, O=16.0), the relative formula mass (Mr) of CaCO3 is 100.1 and CO2 is 44.0. Calculate moles of CaCO3: n = 4.20 / 100.1 = 0.041958 mol. From the balanced equation, the molar ratio of CaCO3 to CO2 is 1:1, so 0.041958 mol of CO2 is produced. Finally, calculate the mass of CO2: mass = n * Mr = 0.041958 * 44.0 = 1.846 g.\",\n  \"key_equations\": [\n    \"n = m / Mr\",\n    \"CaCO3 + 2HCl -> CaCl2 + CO2 + H2O\"\n  ],\n  \"line_refs\": [\n    \"L14\",\n    \"L24\",\n    \"L33\",\n    \"L34\"\n  ],\n  \"checks\": [\n    \"The mass of CO2 should be less than the mass of CaCO3 because CO2 (44) is lighter than CaCO3 (100).\",\n    \"Ratio of masses ~ 44/100 = 0.44. 4.2 * 0.44 = 1.848. Matches result.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P03\",\n  \"final_answer\": {\n    \"value\": 0.0702,\n    \"units\": \"mol dm-3\",\n    \"precision_note\": \"Volumes given to 4 s.f., concentration to 3 s.f. Result reported to 3 significant figures.\"\n  },\n  \"method\": \"Calculate moles of NaOH using c = n/V: n(NaOH) = 0.150 * (23.40/1000) = 0.00351 mol. From the balanced equation H2SO4 + 2NaOH -> Na2SO4 + 2H2O, the ratio is 1:2. So n(H2SO4) = 0.00351 / 2 = 0.001755 mol. Calculate concentration of H2SO4: c = n/V = 0.001755 / (25.00/1000) = 0.0702 mol dm-3.\",\n  \"key_equations\": [\n    \"c = n / V\",\n    \"H2SO4 + 2NaOH -> Na2SO4 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L15\",\n    \"L39\",\n    \"L40\"\n  ],\n  \"checks\": [\n    \"Since 2 moles of NaOH react with 1 mole of H2SO4, and volumes are similar, the concentration of H2SO4 should be roughly half of NaOH.\",\n    \"0.150 / 2 = 0.075. 0.0702 is close to 0.075.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P04\",\n  \"final_answer\": {\n    \"value\": -814,\n    \"units\": \"kJ mol-1\",\n    \"precision_note\": \"Bond energies given as integers (3 significant figures). Result reported to 3 significant figures.\"\n  },\n  \"method\": \"Identify bonds broken in reactants: 4 C-H bonds in CH4 and 2 O=O bonds in 2O2. Energy required = (4 * 413) + (2 * 498) = 1652 + 996 = 2648 kJ. Identify bonds formed in products: 2 C=O bonds in CO2 and 4 O-H bonds in 2H2O. Energy released = (2 * 805) + (4 * 463) = 1610 + 1852 = 3462 kJ. Calculate deltaH = Energy required - Energy released = 2648 - 3462 = -814 kJ mol-1.\",\n  \"key_equations\": [\n    \"deltaH = sum(bonds broken) - sum(bonds formed)\",\n    \"CH4 + 2O2 -> CO2 + 2H2O\"\n  ],\n  \"line_refs\": [\n    \"L45\",\n    \"L46\",\n    \"L47\"\n  ],\n  \"checks\": [\n    \"Combustion is exothermic, so deltaH should be negative.\",\n    \"The value is negative (-814), which is consistent.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P05\",\n  \"final_answer\": {\n    \"value\": 0.889,\n    \"units\": \"g\",\n    \"precision_note\": \"Current and time given to 3 s.f., Faraday constant to 3 s.f., atomic mass to 4 s.f. Result reported to 3 significant figures.\"\n  },\n  \"method\": \"First, convert time to seconds: 30.0 min * 60 = 1800 s. Calculate charge Q = I * t = 1.50 * 1800 = 2700 C. Calculate moles of electrons n(e-) = Q / F = 2700 / 96,500 = 0.027979 mol. From the half-equation Cu2+ + 2e- -> Cu, 2 moles of electrons deposit 1 mole of copper. So n(Cu) = 0.027979 / 2 = 0.013990 mol. Calculate mass m = n * Ar = 0.013990 * 63.55 = 0.889 g.\",\n  \"key_equations\": [\n    \"Q = I * t\",\n    \"n(e-) = Q / F\",\n    \"Cu2+ + 2e- -> Cu\"\n  ],\n  \"line_refs\": [\n    \"L19\",\n    \"L24\",\n    \"L51\",\n    \"L52\"\n  ],\n  \"checks\": [\n    \"1 Ampere is 1 Coulomb per second. 1.5 A for 1800s is 2700 C.\",\n    \"96500 C is 1 mol e-. 2700 is small fraction (~3%). Result 0.89g is reasonable for small current/time.\"\n  ]\n}"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": true,
          "groundingValid": true,
          "errors": [],
          "content": "{\n  \"problem_id\": \"P06\",\n  \"final_answer\": {\n    \"value\": 0.0736,\n    \"units\": \"dimensionless\",\n    \"precision_note\": \"Volume and moles given to 3 significant figures. Result reported to 3 significant figures.\"\n  },\n  \"method\": \"First, calculate the equilibrium concentrations by dividing moles by volume (V = 2.00 dm3). [NO2] = 0.180 / 2.00 = 0.0900 mol dm-3. [N2O4] = 0.220 / 2.00 = 0.110 mol dm-3. Using the expression Kc = [NO2]^2 / [N2O4], calculate Kc = (0.0900)^2 / 0.110 = 0.00810 / 0.110 = 0.073636... The result is 0.0736 (to 3 s.f.).\",\n  \"key_equations\": [\n    \"Kc = [NO2]^2 / [N2O4]\",\n    \"c = n / V\"\n  ],\n  \"line_refs\": [\n    \"L20\",\n    \"L56\",\n    \"L57\",\n    \"L58\"\n  ],\n  \"checks\": [\n    \"Since [NO2] is less than [N2O4] and it is squared, the numerator is small. The denominator is larger than numerator squared. So Kc should be small (< 1).\",\n    \"0.09^2 is approx 0.008. 0.008 / 0.11 is approx 0.07. Matches result.\"\n  ]\n}"
        }
      ],
      "toolTrace": {
        "pass": true,
        "totalCalls": 30,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file",
          "write_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": true,
        "pathPolicyViolations": [],
        "notes": [],
        "calls": [
          {
            "source": "llm",
            "step": 1,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 2,
            "toolName": "list_directory"
          },
          {
            "source": "llm",
            "step": 3,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 4,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 5,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 6,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 7,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 8,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 9,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 10,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 11,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 12,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 13,
            "toolName": "write_file"
          },
          {
            "source": "llm",
            "step": 14,
            "toolName": "read_file"
          },
          {
            "source": "llm",
            "step": 15,
            "toolName": "write_file"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:14:48.140Z"
          },
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": "schemas",
            "timestamp": "2026-02-12T17:15:57.331Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:16:00.663Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_01.schema.json",
            "timestamp": "2026-02-12T17:16:28.762Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_01.json",
            "timestamp": "2026-02-12T17:17:00.341Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_02.schema.json",
            "timestamp": "2026-02-12T17:17:05.130Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_02.json",
            "timestamp": "2026-02-12T17:18:12.959Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_03.schema.json",
            "timestamp": "2026-02-12T17:18:20.171Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_03.json",
            "timestamp": "2026-02-12T17:18:33.841Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_04.schema.json",
            "timestamp": "2026-02-12T17:18:37.594Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_04.json",
            "timestamp": "2026-02-12T17:19:06.260Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_05.schema.json",
            "timestamp": "2026-02-12T17:19:11.910Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_05.json",
            "timestamp": "2026-02-12T17:20:22.497Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/problem_06.schema.json",
            "timestamp": "2026-02-12T17:22:33.301Z"
          },
          {
            "source": "fs",
            "toolName": "write_file",
            "action": "write",
            "path": "output/problem_06.json",
            "timestamp": "2026-02-12T17:22:51.770Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "pass",
          "scores": {
            "faithfulness": 5,
            "coverage": 5,
            "usefulness": 5
          },
          "critical_issues": [],
          "summary": "All six JSON outputs are consistent with the provided report data and equations, with no fabricated quantities or unsupported assumptions. Calculations match the specified formulas and constants: P01 correctly applies c1V1=c2V2 using the given volumes (L16, L29–L30); P02 correctly accounts for 84.0% purity, uses the given Mr values/atomic data, and applies the 1:1 CaCO3:CO2 stoichiometry from the stated equation (L14, L24–L26, L33–L36); P03 correctly uses the titration stoichiometry (1:2) and c="
        }
      }
    },
    {
      "model": "gemini-3-flash-preview",
      "taskId": "tumor-vaccine-ici",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-3-flash-preview-tumor-vaccine-ici-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": false,
      "graderPass": false,
      "durationMs": 346527,
      "agentCostUsd": 0,
      "graderCostUsd": 0.0102095,
      "totalCostUsd": 0.0102095,
      "agentUsage": {
        "promptTokens": 0,
        "cachedTokens": 0,
        "responseTokens": 0,
        "thinkingTokens": 0,
        "totalTokens": 0
      },
      "graderUsage": {
        "promptTokens": 1690,
        "cachedTokens": 0,
        "responseTokens": 480,
        "thinkingTokens": 38,
        "totalTokens": 2208
      },
      "totalUsage": {
        "promptTokens": 1690,
        "cachedTokens": 0,
        "responseTokens": 480,
        "thinkingTokens": 38,
        "totalTokens": 2208
      },
      "modelVersions": [],
      "agentFinalText": "",
      "agentError": "{\"error\":{\"message\":\"{\\n  \\\"error\\\": {\\n    \\\"code\\\": 429,\\n    \\\"message\\\": \\\"Resource exhausted. Please try again later. Please refer to https://cloud.google.com/vertex-ai/generative-ai/docs/error-code-429 for more details.\\\",\\n    \\\"status\\\": \\\"RESOURCE_EXHAUSTED\\\"\\n  }\\n}\\n\",\"code\":429,\"status\":\"Too Many Requests\"}}",
      "outputValidation": [
        {
          "outputFile": "output/study_overview.json",
          "schemaFile": "schemas/study_overview.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "paper: Invalid input: expected object, received undefined",
            "core_question: Invalid input: expected string, received undefined",
            "datasets_or_cohorts: Invalid input: expected array, received undefined",
            "major_limitations: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/quantitative_findings.json",
          "schemaFile": "schemas/quantitative_findings.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "findings: Invalid input: expected array, received undefined",
            "controls_or_null_results: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/claim_audit.json",
          "schemaFile": "schemas/claim_audit.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "claims: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/public_summary.json",
          "schemaFile": "schemas/public_summary.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "headline: Invalid input: expected string, received undefined",
            "plain_language_summary: Invalid input: expected string, received undefined",
            "what_is_new: Invalid input: expected array, received undefined",
            "why_caution_is_needed: Invalid input: expected array, received undefined",
            "glossary: Invalid input: expected array, received undefined",
            "open_questions: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        }
      ],
      "toolTrace": {
        "pass": false,
        "totalCalls": 4,
        "failedCalls": 0,
        "toolsUsed": [
          "list_directory",
          "read_file"
        ],
        "hasSuccessfulRead": true,
        "hasSuccessfulWrite": false,
        "pathPolicyViolations": [],
        "notes": [
          "No successful write tool call observed (write_file/replace/apply_patch)."
        ],
        "calls": [
          {
            "source": "fs",
            "toolName": "list_directory",
            "action": "list",
            "path": ".",
            "timestamp": "2026-02-12T17:10:09.818Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "TASK.md",
            "timestamp": "2026-02-12T17:10:42.333Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "input/report.md",
            "timestamp": "2026-02-12T17:10:47.694Z"
          },
          {
            "source": "fs",
            "toolName": "read_file",
            "action": "read",
            "path": "schemas/study_overview.schema.json",
            "timestamp": "2026-02-12T17:12:32.144Z"
          }
        ]
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 5,
            "coverage": 1,
            "usefulness": 1
          },
          "critical_issues": [
            "All four output JSON files are empty objects (`{}`) and therefore omit essentially all report content (study question, design, cohorts, findings, controls, mechanism, caveats). This fails the 'main findings and caveats are covered' and 'practically useful' criteria.",
            "Schema validity failures are explicit (missing required fields like `paper`, `core_question`, `datasets_or_cohorts`, `major_limitations`, `findings`, `controls_or_null_results`, `claims`, `headline`, etc.). Because required structure is absent, the outputs are not coherent for downstream review.",
            "Grounding/line-referencing cannot be evaluated because the outputs contain no claims and no line references at all, violating the requirement that line references be valid and map to numbered report lines.",
            "Coverage of core quantitative results is completely missing: immunopeptidome expansion (62.3% vs 37.3%; L28), MHC-I peptidome (40.6% vs 20.6%; L29), human p-value p=0.01 (L30), IFN score 3.1 vs 1.0 (L31), PD-L1 2.4x (L32), CD8 density 1.8x (L33).",
            "Controls and conditional results are absent: lack of durable control with vaccine-only in non-immunogenic models (L36), limited ICI-only activity (L37), lipid particle control negative (L38), IFNAR1 blockade abolishing effect (L39).",
            "Major limitations/caveats are absent, including retrospective non-randomized human cohort and confounding (L49), variable vaccination timing (L50), heterogeneity (L51), mouse-to-human generalizability (L52), and model-specific strength (L53)."
          ],
          "summary": "Fail. The provided outputs are empty JSON objects and do not encode the study’s design, cohorts, quantitative findings, controls, mechanistic interpretation, or key caveats from the report (L10–L56). They are also schema-invalid and contain no line-grounded references, making them unusable for downstream scientific review despite not fabricating any numbers."
        }
      }
    },
    {
      "model": "gemini-3-flash-preview",
      "taskId": "gcse-chemistry-8-9",
      "runIndex": 1,
      "workspacePath": "workspaces/gemini-3-flash-preview-gcse-chemistry-8-9-run-1",
      "success": false,
      "schemaPass": false,
      "toolTracePass": false,
      "graderPass": false,
      "durationMs": 20608,
      "agentCostUsd": 0,
      "graderCostUsd": 0.00804825,
      "totalCostUsd": 0.00804825,
      "agentUsage": {
        "promptTokens": 0,
        "cachedTokens": 0,
        "responseTokens": 0,
        "thinkingTokens": 0,
        "totalTokens": 0
      },
      "graderUsage": {
        "promptTokens": 1983,
        "cachedTokens": 0,
        "responseTokens": 300,
        "thinkingTokens": 27,
        "totalTokens": 2310
      },
      "totalUsage": {
        "promptTokens": 1983,
        "cachedTokens": 0,
        "responseTokens": 300,
        "thinkingTokens": 27,
        "totalTokens": 2310
      },
      "modelVersions": [],
      "agentFinalText": "",
      "agentError": "{\"error\":{\"message\":\"{\\n  \\\"error\\\": {\\n    \\\"code\\\": 429,\\n    \\\"message\\\": \\\"Resource exhausted. Please try again later. Please refer to https://cloud.google.com/vertex-ai/generative-ai/docs/error-code-429 for more details.\\\",\\n    \\\"status\\\": \\\"RESOURCE_EXHAUSTED\\\"\\n  }\\n}\\n\",\"code\":429,\"status\":\"Too Many Requests\"}}",
      "outputValidation": [
        {
          "outputFile": "output/problem_01.json",
          "schemaFile": "schemas/problem_01.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/problem_02.json",
          "schemaFile": "schemas/problem_02.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/problem_03.json",
          "schemaFile": "schemas/problem_03.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/problem_04.json",
          "schemaFile": "schemas/problem_04.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/problem_05.json",
          "schemaFile": "schemas/problem_05.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        },
        {
          "outputFile": "output/problem_06.json",
          "schemaFile": "schemas/problem_06.schema.json",
          "exists": true,
          "jsonValid": true,
          "schemaValid": false,
          "groundingValid": false,
          "errors": [
            "problem_id: Invalid input: expected string, received undefined",
            "final_answer: Invalid input: expected object, received undefined",
            "method: Invalid input: expected string, received undefined",
            "key_equations: Invalid input: expected array, received undefined",
            "line_refs: Invalid input: expected array, received undefined",
            "checks: Invalid input: expected array, received undefined"
          ],
          "content": "{}\n"
        }
      ],
      "toolTrace": {
        "pass": false,
        "totalCalls": 0,
        "failedCalls": 0,
        "toolsUsed": [],
        "hasSuccessfulRead": false,
        "hasSuccessfulWrite": false,
        "pathPolicyViolations": [],
        "notes": [
          "Expected at least 3 tool calls, observed 0.",
          "No successful read/list/search tool call observed.",
          "No successful write tool call observed (write_file/replace/apply_patch)."
        ],
        "calls": []
      },
      "grader": {
        "model": "chatgpt-gpt-5.2",
        "value": {
          "verdict": "fail",
          "scores": {
            "faithfulness": 2,
            "coverage": 1,
            "usefulness": 1
          },
          "critical_issues": [
            "All six output JSON files (problem_01.json through problem_06.json) are empty objects `{}` and therefore contain no solutions, no methods, no equations, no checks, and no line references. This fails practical usefulness and coverage requirements.",
            "Schema/grounding failures are explicit: each file is missing required fields (problem_id, final_answer, method, key_equations, line_refs, checks). This makes the outputs unusable for downstream review.",
            "No report line references are provided, so the requirement “Line references are valid and map to the numbered report lines” is not met.",
            "Core outcomes are entirely missing for every problem (P01–P06): there are no computed concentrations/masses/ΔH/Kc values, and no mention of significant figures or caveats per the instructions (L8–L12).",
            "Although there are no fabricated quantitative claims (because there are no claims at all), the absence of content still violates the pass criteria requiring main findings and caveats to be covered and outputs to be coherent/useful."
          ],
          "summary": "Fail: the generated outputs are empty JSON objects for every problem, missing all required fields, computations, and line references. They contain no actionable or reviewable results derived from the report (L28–L60) and therefore are not practically useful."
        }
      }
    }
  ]
}
